Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:54:26 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:54:35 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.12

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 09:54:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1402 TO ITERATE

100.0% PROCESSED    1402 ITERATIONS                          2 ANSWERS
SEARCH TIME: 00.00.01

L2             2 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                           155.42     155.63

FILE 'MARPAT' ENTERED AT 09:55:06 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US     6683216 27 JAN 2004
DE    10317487 12 FEB 2004
EP     1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:55:13 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 188320 TO ITERATE

  2.6% PROCESSED    4928 ITERATIONS                          0 ANSWERS
```

```
  5.2% PROCESSED    9830 ITERATIONS                          0 ANSWERS

  9.6% PROCESSED   17988 ITERATIONS                          0 ANSWERS

 12.3% PROCESSED   23074 ITERATIONS                          0 ANSWERS

 14.7% PROCESSED   27736 ITERATIONS                          0 ANSWERS

 19.0% PROCESSED   35811 ITERATIONS                          0 ANSWERS

 21.6% PROCESSED   40690 ITERATIONS                          0 ANSWERS

 25.4% PROCESSED   47753 ITERATIONS                          0 ANSWERS

 28.0% PROCESSED   52663 ITERATIONS                          0 ANSWERS

 29.5% PROCESSED   55638 ITERATIONS                          0 ANSWERS

 30.6% PROCESSED   57544 ITERATIONS                          0 ANSWERS

 31.3% PROCESSED   58946 ITERATIONS                          0 ANSWERS

 31.6% PROCESSED   59582 ITERATIONS                          0 ANSWERS

 31.9% PROCESSED   60000 ITERATIONS                          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.04.00

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       188320 TO   188320
PROJECTED ANSWERS:               0 TO        0

L3            0 SEA SSS FUL L1

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             111.94     267.57

STN INTERNATIONAL LOGOFF AT 09:59:31 ON 13 MAR 2004
```

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:04:11 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:04:30 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.13

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 10:04:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1146 TO ITERATE

100.0% PROCESSED 1146 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.06

L2 21 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 10:05:08 ON 13 MAR 2004

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
STRUCTURE TOO LARGE - SEARCH ENDED
A structure in your query is too large. You may delete attributes or atoms to reduce the size of the structure and try again.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	156.05

FILE 'CAPLUS' ENTERED AT 10:05:25 ON 13 MAR 2004

FILE COVERS 1907 - 13 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 12 Mar 2004 (20040312/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d l2 fbib hit str abs total
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

```
=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:521746  CAPLUS
DN   137:93770
TI   Preparation of tricyclic spiro compounds and cholesterol biosynthesis
     inhibitors containing them as the active ingredient
IN   Nishida, Hidemitsu; Mukaihira, Takafumi
PA   Mochida Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 311 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 2
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002053568      A1    20020711      WO 2001-JP11656  20011228
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           JP 2000-399998 A 20001228
     EP 1346994          A1    20030924      EP 2001-272922   20011228
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           JP 2000-399998 A 20001228
                                           WO 2001-JP11656W 20011228
PATENT FAMILY INFORMATION:
FAN  2001:31501
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2001002397      A1    20010111      WO 2000-JP4374   20000630
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           JP 1999-222883 A 19990630
     EP 1191028          A1    20020327      EP 2000-940912   20000630
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 W 20000630
     BR 2000012093       A     20020716      BR 2000-12093    20000630
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 W 20000630
     ZA 2001010558       A     20020912      ZA 2001-10558    20011221
                                           JP 1999-222883 A 19990630
```

US 2003045520	A1	20030306	US 2001-26606	20011227
			JP 1999-222883 A	19990630
			WO 2000-JP4374 A2	20000630
			JP 2000-399998 A	20001228
NO 2001006402	A	20020227	NO 2001-6402	20011228
			JP 1999-222883 A	19990630
			WO 2000-JP4374 W	20000630

OS MARPAT 137:93770

IT **318988-28-2P 441790-26-7P 441790-30-3P 441790-31-4P 441790-36-9P 441790-38-1P 441790-44-9P 441790-47-2P 441790-57-4P 441790-81-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 318988-28-2 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-26-7 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-30-3 CAPLUS

CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(4-bromophenyl)sulfonyl]tetrahydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 441790-31-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-36-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-38-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-44-9 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-47-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-57-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-81-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



GI



I

AB Disclosed are orally administrable cholesterol biosynthesis inhibitors and oxidosqualene cyclase inhibitors which contain as the active ingredients tricyclic spiro compds., i.e. 1,4-diaza-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one and 1,4,7-triazaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one derivs. represented by the general formula (I) or salts thereof: [wherein A = H, (un)substituted 5- or 6-membered (un)saturated heterocyclic or carbocyclic group, (un)substituted NH2 or imidoyl; B = a single bond, carbonyl, S(O)x (x = 0,1,2), C1-2 alkylene; D = H, COR5 (R5 = H, substituent), (un)substituted C1-6 alkyl; X = N, CH optionally substituted by A'-B' group (A' and B' are selected from groups defined in A and B, resp.); Y = O, S(O)y (y = 0,1,2), NH; Z = CH2, CO, C(:S); T = SO2, CO, S(O)z (z = 0,1,2), a single bond, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbon or heterocyclic group; m, n, p = 0,1, or 2, provided that m and p are not simultaneously 0; q = 0,1; each of 3 rings cong. X, Y, and Z is optionally substituted; the solid line accompanied by a dotted line represents a single bond or a double bond when q is 0]. These compds. inhibit oxidosqualene cyclase and in turn the conversion of 2,3-oxidosqualene into cholesterol and thereby exhibit potent serum cholesterol lowering effect and are useful for the prevention and/or treatment of cholesterol biosynthesis and oxidosqualene cyclase-related diseases such as hypercholesteremia, hyperlipidemia, arteriosclerotic disease, myocardial infarction, angina pectoris, cerebral infarction, cerebral hemorrhage, aortic aneurysm, peripheral artery obstruction, nephrosclerosis, optic nerve atrophy, hydrocephalus, and fungal infection. Thus, Et3N and 4-bromobenzenesulfonyl chloride were added to a son. of 1,4-diaza-4-(benzyloxycarbonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one in CH2Cl2 and stirred at room temperature for 10 min to give 1,4-diaza-4-(benzyloxycarbonyl)-1'-(4-bromobenzenesulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one which was dissolved in MeCN, treated with trimethylsilyl iodide under ice-cooling, and stirred for 30 min under ice-cooling to give 1,4-diaza-1'-(4-bromobenzenesulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one (II). II at 0.3 μg/mL in vitro inhibited the biosynthesis of cholesterol in mouse fibroblast L929 cells by 66%.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31501 CAPLUS
DN 134:100887
TI Preparation of tricyclic compounds having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants
IN Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya
PA Mochida Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2

DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			JP 1999-222883 A	19990630
	EP 1191028	A1	20020327	EP 2000-940912	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	BR 2000012093	A	20020716	BR 2000-12093	20000630
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	ZA 2001010558	A	20020912	ZA 2001-10558	20011221
				JP 1999-222883 A	19990630
	US 2003045520	A1	20030306	US 2001-26606	20011227
				JP 1999-222883 A	19990630
				WO 2000-JP4374 A2	20000630
				JP 2000-399998 A	20001228
	NO 2001006402	A	20020227	NO 2001-6402	20011228
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630

PATENT FAMILY INFORMATION:
FAN 2002:521746

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053568	A1	20020711	WO 2001-JP11656	20011228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			JP 2000-399998 A	20001228
	EP 1346994	A1	20030924	EP 2001-272922	20011228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-399998 A	20001228
				WO 2001-JP11656W	20011228

OS MARPAT 134:100887
IT **318986-34-4P 318986-44-6P 318986-57-1P**
318986-66-2P 318986-72-0P 318986-89-9P
318987-11-0P 318987-50-7P 318987-59-6P
318988-19-1P 318988-24-8P 318988-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318986-34-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-44-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 318986-57-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 318986-66-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-72-0 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxospiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-89-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 318987-11-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318987-50-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 318987-59-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-19-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl- (9CI) (CA INDEX NAME)



RN 318988-24-8 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 318988-28-2 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



GI



I



II

AB Aromatic compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)saturated 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH2, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted C1-2 alkylene; D = H, (un)substituted CHO, (un)substituted C1-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)y (wherein y = 0,1,2), (un)substituted NH; Z = CH2, CO, C(S); T = S(O)z (wherein z = 0,1,2), CO, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings containing X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring containing Z is a single bond or a double bond when p = 0] are prepared These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC6H4SO3H.H2O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one which underwent saponification with a mixture of aqueous NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one hydrochloride. The latter compound was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one (II; R = CH2OMe). II (R = CH2OMe) and II (R = CO2Et) showed IC50 of 0.0032 and 0.0015 μM, resp., against Fxa.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	23.43	179.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.39	-1.39

STN INTERNATIONAL LOGOFF AT 10:07:03 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Patel <3/13/2004>

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:11:49 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:11:59 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 09:12:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     522 TO ITERATE

100.0% PROCESSED     522 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L2             2 SEA SSS FUL L1

=> file marpar
'MARPAR' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> s l2 sss full
FULL SEARCH INITIATED 09:12:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     522 TO ITERATE

100.0% PROCESSED     522 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L3             2 SEA SSS FUL L1

=> file caol;d
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   310.84     311.05

FILE 'CAOLD' ENTERED AT 09:12:58 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n
```

```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42     311.47

FILE 'CAOLD' ENTERED AT 09:13:07 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l1 sss full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



FULL SEARCH INITIATED 09:13:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     522 TO ITERATE

100.0% PROCESSED     522 ITERATIONS                          2 ANSWERS
SEARCH TIME: 00.00.01

L4             2 SEA SSS FUL L1



L5             0 L4

=> file CAREACT
'CAREACT' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAOLD'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> ignore
IGNORE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
```

For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> "IGNORE"
"IGNORE" IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	467.73

FILE 'CAPLUS' ENTERED AT 09:14:06 ON 13 MAR 2004

FILE COVERS 1907 - 13 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 12 Mar 2004 (20040312/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 09:11:49 ON 13 MAR 2004)

FILE 'REGISTRY' ENTERED AT 09:11:59 ON 13 MAR 2004
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS FULL
L3 2 S L2 SSS FULL

FILE 'CAOLD' ENTERED AT 09:12:58 ON 13 MAR 2004

FILE 'CAOLD' ENTERED AT 09:13:07 ON 13 MAR 2004
S L1

FILE 'REGISTRY' ENTERED AT 09:13:15 ON 13 MAR 2004
L4 2 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 09:13:16 ON 13 MAR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:14:06 ON 13 MAR 2004

=> s l2
L6 1 L2

=> s l3
L7 1 L3

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31501 CAPLUS
DN 134:100887
TI Preparation of tricyclic compounds having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants
IN Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya
PA Mochida Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-222883 A	19990630
	EP 1191028	A1	20020327	EP 2000-940912	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	BR 2000012093	A	20020716	BR 2000-12093	20000630
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	ZA 2001010558	A	20020912	ZA 2001-10558	20011221
				JP 1999-222883 A	19990630
	US 2003045520	A1	20030306	US 2001-26606	20011227
				JP 1999-222883 A	19990630
				WO 2000-JP4374 A2	20000630
				JP 2000-399998 A	20001228
	NO 2001006402	A	20020227	NO 2001-6402	20011228
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630

PATENT FAMILY INFORMATION:

FAN 2002:521746

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053568	A1	20020711	WO 2001-JP11656	20011228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM .
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2000-399998 A 20001228

EP 1346994 A1 20030924 EP 2001-272922 20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2000-399998 A 20001228
WO 2001-JP11656W 20011228

OS MARPAT 134:100887

IT **318988-48-6P**, 1,4-Diaza-6-(hydroxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one **318988-58-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318988-48-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 318988-58-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro- (9CI) (CA INDEX NAME)



GI



I



II

AB Aromatic compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)saturated 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH2, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted C1-2 alkylene; D = H, (un)substituted CHO, (un)substituted C1-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)y (wherein y = 0,1,2), (un)substituted NH; Z = CH2, CO, C(S); T = S(O)z (wherein z = 0,1,2), CO, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings containing X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring containing Z is a single bond or a double bond when p = 0] are prepared These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC6H4SO3H.H2O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one which underwent saponification with a mixture of aqueous NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one hydrochloride. The latter compound was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one (II; R = CH2OMe). II (R = CH2OMe) and II (R = CO2Et) showed IC50 of 0.0032 and 0.0015 μM, resp., against Fxa.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 fbib hitstr abs total

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31501 CAPLUS
DN 134:100887
TI Preparation of tricyclic compounds having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants
IN Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya
PA Mochida Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-222883 A	19990630
	EP 1191028	A1	20020327	EP 2000-940912	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	BR 2000012093	A	20020716	BR 2000-12093	20000630
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	ZA 2001010558	A	20020912	ZA 2001-10558	20011221
				JP 1999-222883 A	19990630
	US 2003045520	A1	20030306	US 2001-26606	20011227
				JP 1999-222883 A	19990630
				WO 2000-JP4374 A2	20000630
				JP 2000-399998 A	20001228
	NO 2001006402	A	20020227	NO 2001-6402	20011228
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630

PATENT FAMILY INFORMATION:
FAN 2002:521746

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053568	A1	20020711	WO 2001-JP11656	20011228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

JP 2000-399998 A 20001228
EP 1346994 A1 20030924 EP 2001-272922 20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2000-399998 A 20001228
WO 2001-JP11656W 20011228

OS MARPAT 134:100887

IT **318988-48-6P**, 1,4-Diaza-6-(hydroxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one **318988-58-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318988-48-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 318988-58-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro- (9CI) (CA INDEX NAME)



GI



I



II

AB Aromatic compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)saturated 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH2, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted C1-2 alkylene; D = H, (un)substituted CHO, (un)substituted C1-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)y (wherein y = 0,1,2), (un)substituted NH; Z = CH2, CO, C(S); T = S(O)z (wherein z = 0,1,2), CO, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings containing X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring containing Z is a single bond or a double bond when p = 0] are prepared These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC6H4SO3H.H2O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one which underwent saponification with a mixture of aqueous NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one hydrochloride. The latter compound was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one (II; R = CH2OMe). II (R = CH2OMe) and II (R = CO2Et) showed IC50 of 0.0032 and 0.0015 μM, resp., against Fxa.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s oxaspiro and bicyclo

```
L8          50 OXASPIRO AND BICYCLO

=> s l8 and nonan and 2-one
L9           3 L8 AND NONAN AND 2-ONE

=> d l9 fbib hitstr abs total

L9   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:31501  CAPLUS
DN   134:100887
TI   Preparation of tricyclic compounds having spiro-piperidine as inhibitors
     of blood coagulation factor X (FXa) and anticoagulants
IN   Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya
PA   Mochida Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 305 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 2
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2001002397      A1    20010111      WO 2000-JP4374   20000630
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           JP 1999-222883 A 19990630
     EP 1191028          A1    20020327      EP 2000-940912   20000630
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 W 20000630
     BR 2000012093       A     20020716      BR 2000-12093    20000630
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 W 20000630
     ZA 2001010558       A     20020912      ZA 2001-10558    20011221
                                           JP 1999-222883 A 19990630
     US 2003045520       A1    20030306      US 2001-26606    20011227
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 A220000630
                                           JP 2000-399998 A 20001228
     NO 2001006402       A     20020227      NO 2001-6402     20011228
                                           JP 1999-222883 A 19990630
                                           WO 2000-JP4374 W 20000630

PATENT FAMILY INFORMATION:
FAN  2002:521746
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002053568      A1    20020711      WO 2001-JP11656  20011228
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2000-399998 A 20001228
EP 1346994 A1 20030924 EP 2001-272922 20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2000-399998 A 20001228
WO 2001-JP11656W 20011228

OS MARPAT 134:100887
GI



I



II

AB Aromatic compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)saturated 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH2, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted C1-2 alkylene; D = H, (un)substituted CHO, (un)substituted C1-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)y (wherein y = 0,1,2), (un)substituted NH; Z = CH2, CO, C(S); T = S(O)z (wherein z = 0,1,2), CO, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings containing X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring containing Z is a single bond or a double bond when p = 0] are prepared These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC6H4SO3H.H2O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-**oxaspiro**[**bicyclo**[4.3.0]**nonan**-8,4'-piperidine]-

2-one which underwent saponification with a mixture of aqueous NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-**oxaspiro[bicyclo** [4.3.0]**nonan**-8,4'-piperidine]-**2-one** hydrochloride. The latter compound was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[**bicyclo** [4.3.0]**nonan**-8,4'-piperidine]-**2-one** (II; R = CH2OMe). II (R = CH2OMe) and II (R = CO2Et) showed IC50 of 0.0032 and 0.0015 μM, resp., against Fxa.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:531398 CAPLUS
DN 117:131398
TI A general methodology for the synthesis of linearly fused polyquinanes.
AU Murthy, Y. V. Suryanarayana; Pillai, C. Narayana
CS Dep. Chem., Indian Inst. Technol., Madras, 600 036, India
SO Tetrahedron (1992), 48(25), 5331-46
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 117:131398
GI



I



II



III



IV

AB A methodol. involving a combination of spiro-annulation by the action of 1,4-dibromomagnesiobutane on succinic acid derivs. followed by cyclization of the spirolactone using P2O5-CH3SO3H reagent was developed for the synthesis of polyquinanes. By using **bicyclo** [2.2.1]heptanecarboxylic acids I and II as the precursors for the spirolactones, triquinane III and pentaquinane IV were synthesized.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:61590 CAPLUS
DN 114:61590
TI A new route to linearly fused polyquinanes
AU Murty, Narayana Y. V. S.; Pillai, C. Narayana
CS Dep. Chem., Indian Inst. Technol., Madras, 600 036, India
SO Tetrahedron Letters (1990), 31(42), 6067-70
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 114:61590
GI



I



II

AB Syntheses of the triquinane I and the C17-pentaquinane II are reported starting from **bicyclo**[2.2.1]heptane derivs. utilizing di-Grignard species as key reagents.

=> d his

(FILE 'HOME' ENTERED AT 09:11:49 ON 13 MAR 2004)

FILE 'REGISTRY' ENTERED AT 09:11:59 ON 13 MAR 2004
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS FULL
L3 2 S L2 SSS FULL

FILE 'CAOLD' ENTERED AT 09:12:58 ON 13 MAR 2004

FILE 'CAOLD' ENTERED AT 09:13:07 ON 13 MAR 2004
S L1

FILE 'REGISTRY' ENTERED AT 09:13:15 ON 13 MAR 2004
L4 2 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 09:13:16 ON 13 MAR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:14:06 ON 13 MAR 2004
L6 1 S L2
L7 1 S L3
L8 50 S OXASPIRO AND BICYCLO
L9 3 S L8 AND NONAN AND 2-ONE

=> s l8 and decan
L10 5 L8 AND DECAN

=> s l10 and one
L11 5 L10 AND ONE

=> d l11 fbib hitstr abs total

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:531398 CAPLUS
DN 117:131398
TI A general methodology for the synthesis of linearly fused polyquinanes.
AU Murthy, Y. V. Suryanarayana; Pillai, C. Narayana
CS Dep. Chem., Indian Inst. Technol., Madras, 600 036, India
SO Tetrahedron (1992), 48(25), 5331-46
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 117:131398
GI



I



II



III



IV

AB A methodol. involving a combination of spiro-annulation by the action of 1,4-dibromomagnesiobutane on succinic acid derivs. followed by cyclization of the spirolactone using P2O5-CH3SO3H reagent was developed for the synthesis of polyquinanes. By using **bicyclo** [2.2.1]heptanecarboxylic acids I and II as the precursors for the spirolactones, triquinane III and pentaquinane IV were synthesized.

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:23388 CAPLUS
DN 110:23388
TI An asymmetric intramolecular alkylation to form a **bicyclo** [3.1.0]hexanone derivative
AU Hamon, David P. G.; Shirley, Neil J.
CS Dep. Org. Chem., Univ. Adelaide, Adelaide, 5001, Australia
SO Journal of the Chemical Society, Chemical Communications (1988), (6), 425-6
CODEN: JCCCAT; ISSN: 0022-4936

DT Journal
LA English
OS CASREACT 110:23388
GI



AB (-)-(Hydroxymethyl)**oxaspiro**[2.5]octanone I, prepared in ≥90% enantiomeric excess by asym. epoxidn. of the allylic alc. precursor, undergoes intramol. cyclopropanation upon treatment with base to give (dihydromethylethyl)bicyclohexanone II with high diastereoselectivity.

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:42507 CAPLUS
DN 74:42507
TI Cyclopropanol derivatives as intermediates for organochemical synthesis
AU Wenkert, Ernest; Mueller, Richard August; Reardon, Edward J., Jr.; Sathe, S. S.; Scharf, D. J.; Tosi, Giorgio
CS Dep. Chem., Indiana Univ., Bloomington, IN, USA
SO Journal of the American Chemical Society (1970), 92(25), 7428-36
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CASREACT 74:42507
AB A terpene synthesis via the acid-induced transformations of cyclopropyl ethers and β-methoxycyclopropylcarbinols into quaternary α-methyl and α-vinyl carbonyl compds., resp., and similar reactions with gem-dimethoxycyclopropanes are described. A cyclopropylamine is inert. β-Methoxycyclo-propanecarboxylic esters are converted into γ-oxo carboxylic acid derivs. A similar ring unravelling of a β-acetoxycyclopropyl ketone is used for the synthesis of dihydrojasmone. An α-methoxycyclopropylcarbinol is transformed into a cyclobutanone on acid treatment and a mechanistically related cyclobutanone interconversion process is used for the preparation of a bicyclic intermediate of the bourbonene sesquiterpenes.

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:52824 CAPLUS
DN 58:52824
OREF 58:8922g-h,8923a-b
TI Synthesis and transformations of acetylenic α-glycols with a free acetylenic hydrogen. VI. Preparation of 3-(1-hydroxycyclohexyl)-1-butyn-3-ol and its conversions under influence of sulfuric acid
AU Favorskaya, T. A.; Samusik, B. N.
CS State Univ., Leningrad
SO Zhurnal Obshchei Khimii (1962), 32, 2128-34

CODEN: ZOKHA4; ISSN: 0044-460X
DT Journal
LA Unavailable
OS CASREACT 58:52824
GI For diagram(s), see printed CA Issue.
AB cf. CA 54, 24620f; 55, 23325h. Cyclohexanol and C2H2 in presence of KOH gave 1-ethynylcyclohexanol, m. 21°, b14 89-1°, which added at 30-40° to HgO in 25% H2SO4 and stirred 4-5 hrs. gave 80% 1-acetylcyclohexanol, b7 74-5°, n20D 1.4711, and 5% I, b7 135-7°, m. 108-9°. To Na, dissolved in liquid NH3 in the presence of a catalytic amount of Fe(NO3)3 in the presence of air, was added C2H2 over 2 hrs., followed by 1-acetylcyclohexanol in Et2O; after 12 hrs. the mixture was treated with aqueous NH4Cl, and gave 65% 3-(1-hydroxycyclohexyl)-1-butyn-3-ol (II), m. 64-5°, b15 127-8°. II suspended in CCl4 was added over 1 hr. to concentrated H2SO4, at -14° and stirred 1 hr.; after treatment with ice, it gave some 2-methyl-2-ethynylsuberone (II), b10 73-7° (2,4-dinitrophenylhydrazone m. 198-9°), and a fraction, b18 119-22°, which was purified by treatment with KMnO4 and gave 15% 3-methyl-2,2-pentamethylene-4-oxotetrahydrofuran (IV), b21 126-8°, n20D 1.4730, d20 1.0272 (2,4-dinitrophenylhydrazone m. 164.5-5°). II and KMnO4 gave 90% 2-methylsuberone, b22 80-1°, n20D 80-1°, n20D 1.4581, and AcOH, along with Ac(CH2)3CO2H and adipic acid. IV and 30% KOH gave a distillate containing 2-methylsuberone and AcOH. III hydrogenated over Pd-CaCO3 to 2-methyl-2-ethylsuberone, b4 67-8°, n20D 1.4612, d20 0.9280; 2,4-dinitrophenylhydrazone m. 81-2°.

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1951:8765 CAPLUS
DN 45:8765
OREF 45:1589f-i,1590a-i,1591a-i,1592a
TI Piperidine and azabicyclo compounds. I. Via Michael condensations
AU Albertson, Noel F.
CS Sterling-Winthrop Research Inst., Rensselaer, NY
SO Journal of the American Chemical Society (1950), 72, 2594-9
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
OS CASREACT 45:8765
GI For diagram(s), see printed CA Issue.
AB Since so many piperidine compds. show marked physiol. activity, their synthesis, by catalytic reduction to piperidines and **bicyclo** N compds. of δ-keto nitriles prepared by Michael condensations between vinyl ketones and cyanoacetic esters or between CH2:CHCN (I) and β-ketones, was reinvestigated. Adding 600 ml. AcCH2CO2Et (II) to 3 g. Na in 400 ml. EtOH, followed by 246 ml. I at such a rate that the temperature did not exceed 45°, distilling off the EtOH, washing the residue with H2O containing 10 ml. AcOH, and distilling gave 63% AcCH(CO2Et)(CH2)2CN (III), b2 121°, n25D 1.4446, and a residue of AcC(CO2Et)(CH2CH2CN)2 (C.A. 23,834). Adding 200 g. III to 200 g. Na2CO3 in 1800 ml. H2O, refluxing 4 hrs., salting out with K2CO3, and extracting with Et2O gave 71% Ac(CH2)3CN (IV), b5.2 86.5°, n25D 1.4790 (2,4-dinitrophenylhydrazone, m. 154-5°). IV may also be prepared from I and Me2CO, but the yield is very low (8.6%) because of polycyanoethylation. β-Keto esters give

much higher yields of (CH2)2CN derivs. than do ketones. Reduction of IV with Raney Ni gave 85% MeC.(CH2)4.NH. Addition of 168 g. AcCH(CH2Ph)CO2Et (V) to 0.5 g. Na in 200 ml. 95% EtOH, followed by 53 ml. I at such a rate that the temperature remained at 25-35°, acidification with alc. HCl 0.5 hr. after the addition of I, and distillation gave 141 g. (85%) AcC(CH2Ph)(CO2Et)(CH2)2CN, b1.5 172°, n25D 1.5068, and 35 g. V. Use of com. absolute EtOH gave PhCH2CH(CO2Et)(CH2)2CN, b2.0 152°, n25D 1.5002, as major or sole product by loss of an Ac group. Addition of 512 g. CH2.CH2.CHAc.CO.O to 2 g. Na in 300 ml. EtOH, followed by 290 ml. I, acidification of the mixture after 1 hr., and allowing to stand 1-2 days gave 86-92% CH2.CH2.CAc(CH2CH2CN).CO.O (VI), m. 44-6° (from MeOH), b1.5 162°, n25D 1.4790, which on refluxing 6 hrs. with 10% aqueous Na2CO3, salting out with K2CO3, extracting with iso-PrOH, and distilling gave a poor yield of yellow oil, b3.5 115-46° [2,4-dinitrophenylhydrazone, m. 159° (from AcOEt)]. VI (40 g.) hydrolyzed by 80 g. KOH in aqueous MeOH, acidified, extracted with AcOEt, and concentrated gave 22 g. α-(2-hydroxyethyl)glutaric acid lactone, b1.0 163-6°. BzCH(CO2Et)(CH2)2CN (VII) (100 g.), refluxed 10 hrs. with 100 g. Na2CO3 and 900 ml. H2O, extracted with Et2O, dried, and distilled gave 37.0 g. (52%) Bz(CH2)3CN, b0.1 125°, n25D 1.5326, and 4 g. Bz(CH2)3CONH2 (VIII), m. 140-1° (from H2O). VIII was also prepared by condensing I with AcCHBzCO2Et and hydrolyzing the condensation product with Na2CO3 solution Addition of 122 g. III and 50 ml. MeI to 15.3 g. Na in 300 ml. dry EtOH and working up the mixture in the usual manner after 2 days' standing gave, on distillation, 35.6 g. NC(CH2)2CHMeCO2Et, b0.8 74-80°, n25D 1.4270, and 63.6 g. AcCMe(CO2Et)(CH2)2CN, b0.8 109°, n25D 1.4461. AcC(CHMe2)(CO2Et)(CH2)2CN, b0.1 121° n25D 1.4542, was prepared in 37% yield by the method of Koelsch and Walker (C.A. 45, 1135f) and in poorer yield from III, iso-Pr2O, and BF3 by the method used by Hauser and Breslow (C.A. 34, 7875.6) to alkylate II. Other keto nitriles, AcCRR'CH2CH2CN, prepared in a manner analogous to III: (R, R', yield (%), b.p. °C. (mm.), n25D resp., given): CH2CH2CO2Me, CO2Et, 100, 166° (1.7), 1.4510; CH2CH2CO2Et, CO2Et, 82, 168° (0.8), 1.4578; CH2Ph, CO2Me, 56, 163° (0.2), 1.5158; C6H13, CO2Et, 73, 157° (2.9), 1.4511; C7H15, CO2Et, 81, 145° (0.9), 1.4505; iso-Bu, CO2Et, 60, 125° (0.1), 1.4528. Also prepared were CO.CH2.CH2.CH2.C(CO2Et)(CH2)2CN, 82, 145° (1.5), 1.4663; AcC(CH2CH2CN).CH2.C(CH2Cl).O.CO, 61, 199° (1.6), 1.4982; and BzCH(CO2Et)(CH2)2CN, 86, 176° (0.7), 1.5131. AcC(CH2OH)(CO2Et)(CH2)2CN, n25D 1.4585, was obtained in 94% yield from IV and formalin. Reduction of 93 g. AcC(CO2Et)(CH2CH2CO2Me)(CH2)2CN in 400 ml. EtOH by Raney Ni and H at 100° and 50 lb. pressure for 6 hrs., removal of the EtOH in vacuo, and filtration from dilute Et2O gave 36% 5-carbethoxy-9-methyl-2-oxo-1-azabicyclo[3.3.1]nonane, m. 170.4-1.3° (corrected, from EtOH). The Et2O solution gave 37.9 g. (43%) Et 3-(2-carbomethoxyethyl)-2-methylnipecotate, b1.4 139°, n25D 1.4740.

A solution of 115 g. Et 2-(2-cyanoethyl)cyclopentan-1-**one**-2-carboxylate in 400 ml. EtOH reduced by Raney Ni and H at 120° and 400 lb. pressure for 7 hrs. gave, on distillation, 79 g. (73%) 4a-carbethoxyoctahydro-1-pyrindine (IX), b0.6 87°, n25D 1.4799 (cf. Henecka, Fr. 881,360), and 14.7 g. of a yellow oil, b0.4 153-209°, n25D 1.4852-8, m. 52.9-4.8° (corrected, from Et2O), which may be the alc. obtained by reduction of the C:O bond. Reduction of 1 mole VI in 400 ml. MeOH by Raney Ni and H at 90° and 500 lb. pressure for 6 hrs. and treatment of the product with alc. HCl gave 62 g. 1-methyl-2-aza-8-**oxaspiro**[5.4]**decan**-7-**one**-HCl (X), m. 265-6.4° (corrected, from EtOH). Hydrogenation of 116.2 g. Et 2-methylnipecotate in 400 ml. EtOH and 68 ml. 37% formalin at 25°

and 400 lb. pressure with a buffered Pd-C catalyst required less than 45 min., giving on distillation 122.2 g. (98%) Et 1,2-dimethylnipecotate (XI), b0.2 73°, n25D 1.4557 [methiodide, m. 185.0-6.4° (corrected)]. The following piperidines (Xa) were prepared in a similar fashion (R1, R2, R3, R4, % yield, b.p. °C. (mm.), n25D, resp.): H, Me, H, H, 85, 117° (760), 1.444; H, Me, H, CO2Et, 86, 59° (0.5), 1.4557 [1-PhNHCO derivative, m. 134.6-6.0° (corrected)]; Me, Me, H, CO2H, -, - (-), - [HCl salt, m. 185.8-8° (corrected)]; H, Me, Me, CO2Et, 89, 63° (0.1), 1.4581 [HCl salt, m. 164.4-5.0° (corrected)]; Me, Me, Me, CO2Et, 58, 67° (0.9), 1.4592; H, Me, iso-Pr, CO2Et, 84, 91° (0.3), 1.4666; Me, Me, iso-Pr, CO2Et, 82, 92° (0.6), 1.4642; H, Me, iso-Bu, CO2Et, 91, 98° (0.3), 1.4658; Me, Me, iso-Bu, CO2Et, 84, 95° (0.9), 1.4612; H, Me, C6H13, CO2Et, 85, 106° (0.2), 1.4627; Me, Me, C6H13, CO2Et, 80, 130° (1.9), 1.4609; H, Me, C7H15, CO2Et, 63, 120° (0.7), 1.4665; Me, Me, C7H15, CO2Et, 33, 136° (1.5), 1.4638; Me, Me, PhCH2, CO2Et, 81, 134° (0.2), 1.5110; H, Me, PhCH2, CO2Me, 78, 137° (0.6), 1.5335; Me, Me, PhCH2, CO2Me, 75, 132° (0.8), 1.5223; H, Me, Ph, CO2Et, 57, 131° (0.3), 1.5323; H, Me, -(CH2)2OCO-, 30, - (-), - (HCl salt, m. 265-6°); Me, Me, -(CH2)2OCO-, 70, - (-), - (HCl salt, m. 72-5°); Me, -(CH2)3-, CO2Et, 85, 83° (1.0), 1.4755; H, Me, (CH2)2CO2Et, CO2Et, 65, 133° (0.9), 1.4740; Me, Me, (CH2)2CO2Et, CO2Et, 86, 128° (1.0), 1.4726; H, Me, (CH2)3NH2, Me, 77, 80° (1.2), 1.5031 (b760 250-5°; di-HCl salt, m. 243-6°; monopicrate, m. 194-5°); H, Ph, H, H, 80, 80° (0.2), 1.5232 (readily hydrated on shaking with H2O); Me, Ph, H, CO2Et, 94, 116° (0.1), 1.5178. Reduction of 90 g. III in 400 ml. EtOH by Raney Ni and H at 60° and 600 lb. pressure for 1-3 hrs./mole H gave 89-93% 5-carbethoxy-6-methyltetrahydro-2-pyronimine, b0.9 103-6°, n25D 1.5350 (supercooled, solid at room temperature), which loses NH3 on refluxing with HCl and is undoubtedly identical with Henecka's 1-cyanopentan-4-ol-3-carboxylic ester (C.A. 44, 2520c). Reduction of γ-cyano esters with Raney Ni gave only piperidines, usually in high yield, while reduction of III gave 86% XI. These results are in marked contrast to those of Henecka (see above), who stated that III does not give a piperidine on reduction unless first converted to the corresponding β-aminocrotonic ester with NH3. Reduction of 165 g. VII in 335 ml. EtOH with Raney Ni and H at 115° and 700 lb. pressure for 1 hr. and distillation gave 113.1 g. (73%) Et 2-phenylnipecotate, b0.08 113°, n25D 1.5227 [HCl salt, m. 202.2-3.4° (corrected); phosphate, m. 183.3-4.9° (corrected)], some BzH, and 19.3 g. of an oil depositing crystals of 5-carbethoxy-6-phenyltetrahydro-2-pyronimine, m. 106.2-8.4° (corrected) (from petr. ether, AcOEt, and iso-PrOH successively). 4-(2,3-Dimethoxyphenyl)-3-buten-2-**one** (XII), b1.1 135-9°, n25D, 1.5810 (70% yield), and AcCH2CHPhCH(CN)CO2Et, b0.8 160-5°, n25D 1.5102, were prepared in the usual manner. Addition of CH(CN)EtCO2Et (XIII) to PhCH:CHAc gave 23% AcCH2CHPhCEt(CN)CO2Et, b1.4 153-61° (decomposition), n25D 1.5050. A solution of 103 g. XII and 71 g. XIII in 100 ml. EtOH, just basic to EtONa, warmed 2.5 hrs. on a steam bath, acidified with alc. HCl, concentrated, and distilled gave 129 g. of an oil, b1.5 55-151°, which on treatment with EtONa and 3 days' standing gave 96.5 g. Et 2-cyano-2-ethyl-3-(2,3-dimethoxyphenyl)-5-oxohexanoate, b1.5-2.4 160-97°, n25D 1.5168 (supercooled), m. 91-4° (from EtOH). Octahydro-4-methyl-1H-quinolizine(?) (HCl salt, m. above 360°; cf. Lukes and Sorm, C.A. 42, 7780d) and 1-(2-piperidyl)-4-pentanol were prepared by reduction of 1-(2-pyridyl)-4-pentanone by Raney Ni and H at 150° and 250 lb.

pressure (Boekelheide and Rothchild, C.A. 43, 4267e). AcCH2Ac (50 g.), 1.5 g. Na, and 108 g. 2-vinylpyridine refluxed 7 hrs. and distilled gave 14.1 g. 1-(2-pyridyl)-4-pentanone (XIV), b1 84-118°, and 37.4 g. of the 3-Ac derivative of XIV, b1 118-19°. The following piperidines (XV) were prepared by the Raney Ni reduction of the keto nitriles in EtOH or by reductive methylation of the piperidines with formalin and a Pd-C catalyst as previously described (R1, R2, R3, b.p. (mm.), n25D, resp.): H, H, Ph, 130° (1.0), 1.5172; Me, H, Ph, 127° (1.5), 1.5104; H, Et, Ph, 131° (1.6), 1.5148; Me,Et, Ph, 118° (0.6), 1.5105; H, Et, 2,3-(MeO)2C6H3, 158° (0.8), 1.5194; Me, Et, 2,3-(MeO)2C6H3, 153° (0.9), 1.5152. Whereas reduction of α-(2-cyanoethyl)acetoacetic esters gave principally piperidines, reduction of Et α-[2-(2-pyridyl)ethyl]acetoacetate in EtOH with Raney Ni at 150° gave 40% Et octahydro-4-methyl-1H-quinolizine-3-carboxylate and 45% octahydro-3-(1-hydroxyethyl)-4-oxo-4H-quinolizine, the piperidone type of ring closure predominating. Of the mols. having more than 1 asym. C atom, only a single dl-modification is obtained on reduction. Nearly all these piperidines and **bicyclo** compds. have been prepared in only 3 steps from readily available and cheap materials. Some of these compds. show mild analgesic activity.

```
=> d his

     (FILE 'HOME' ENTERED AT 09:11:49 ON 13 MAR 2004)

     FILE 'REGISTRY' ENTERED AT 09:11:59 ON 13 MAR 2004
L1             STRUCTURE UPLOADED
L2           2 S L1 SSS FULL
L3           2 S L2 SSS FULL

     FILE 'CAOLD' ENTERED AT 09:12:58 ON 13 MAR 2004

     FILE 'CAOLD' ENTERED AT 09:13:07 ON 13 MAR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 09:13:15 ON 13 MAR 2004
L4           2 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 09:13:16 ON 13 MAR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:14:06 ON 13 MAR 2004
L6           1 S L2
L7           1 S L3
L8          50 S OXASPIRO AND BICYCLO
L9           3 S L8 AND NONAN AND 2-ONE
L10          5 S L8 AND DECAN
L11          5 S L10 AND ONE

=> s oxaspiro and tricyclo
L12         12 OXASPIRO AND TRICYCLO

=> d l12 fbib hitstr abs total

L12  ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:863865  CAPLUS
```

DN 139:69303
TI Product subclass 42: γ-silyl alkyl halides, alcohols, and esters thereof
AU Michael, J. P.; de Koning, C. B.
CS Molecular Science Institute, School of Chemistry, University of Witwatersrand, Johannesburg, 2050, S. Afr.
SO Science of Synthesis (2002), 4, 947-971
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
AB A review describes various methods for the synthesis of γ-silyl alkyl halides, alcs., and esters, and their applications. The methods described include the synthesis from silyl anions and functionalized three-carbon electrophiles; from silicon electrophiles and functionalized three-carbon nucleophiles; from α-silylated carbanions and epoxides; hydrosilylation of allylic compds.; coupling between vinylsilanes and aldehydes or ketones; addns. of allylsilanes; addition of β-silylated carbanions to aldehydes and ketones; and other miscellaneous methods.
RE.CNT 118 THERE ARE 118 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:419363 CAPLUS
DN 123:33413
TI Functionalized bicyclo[2.2.2]octenones: synthesis and crystal structure of endo-4,5-dihydrospiro[furan-2(3H),8'-**tricyclo**[5.2.2.02,6]undeca-3',10'-dien]-9'-one
AU Singh, Vishwakarma; Bedekar, Ashutosh V.; Caira, Mino R.
CS Dep. Chem., Fac. Sci., Univ. Baroda, Baroda, 390 002, India
SO Journal of Chemical Research, Synopses (1995), (2), 45
CODEN: JRPSDC; ISSN: 0308-2342
PB Royal Society of Chemistry
DT Journal
LA English
AB A facile synthesis of the title compound, a potential intermediate for triquinanes, by π4s + π2s cycloaddn. of in situ-generated 1-**oxaspiro**[4,5]deca-7,9-dien-6-one and cyclopentadiene is reported. The structure and stereochem. of the adduct has been determined by single-crystal x-ray anal.

L12 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:409498 CAPLUS
DN 121:9498
TI Synthesis and evaluation of (piperidinomethylene)bis(phosphonic acid) derivatives as anti-osteoporosis agents
AU Mimura, Mitsuo; Hayashida, Mitsuo; Nomiyama, Kiyoshi; Ikegami, Satoru; Iida, Yasuhito; Tamura, Makoto; Hiyama, Yoshiyuki; Ohishi, Yoshitaka
CS Cent. Res. Inst., Kaken Pharm. Co., Ltd., Kyoto, 607, Japan
SO Chemical & Pharmaceutical Bulletin (1993), 41(11), 1971-86
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
GI



I II

AB Some (piperidinomethylene)bis(phosphonic acid) derivs. were prepared and their activity to inhibit a rise in serum calcium induced by parathyroid hormone in thyroparathyroidectomized rats was evaluated. Several (4-alkylidene-, 4,4-dialkyl-, or 4-alkyl-4-halopiperidinomethylene)bis(pho sphonic acid) derivs. showed considerable inhibitory activity. Compds. having aromatic and polar substituents such as azido, hydroxy, amino and amido on the piperidine ring were generally inactive. In this study, two 4-alkylidene compds. I (R = H, Me) (8a, b) and a 4,4-cyclic dialkyl compound II (61) showed potent activity when administered either i.v. or perorally.

L12 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:271187 CAPLUS
DN 120:271187
TI Preparation of antiherpes peptide derivatives having a ureido N-terminus
IN Deziel, Robert; Moss, Neil; Plante, Raymond
PA Bio-Mega/Boehringer Ingelheim Research Inc., Can.
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 560274	A1	19930915	EP 1993-103734	19930309
	EP 560274	B1	19980624		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-849922 A	19920312
	AT 167682	E	19980715	AT 1993-103734	19930309
				US 1992-849922 A	19920312
	ZA 9301746	A	19931006	ZA 1993-1746	19930311
				US 1992-849922 A	19920312
	HU 63853	A2	19931028	HU 1993-697	19930311
				US 1992-849922 A	19920312
	JP 06041189	A2	19940215	JP 1993-49767	19930311
				US 1992-849922 A	19920312
	CA 2092652	AA	19930913	CA 1993-2092652	19930312
	CA 2092652	C	20010724		
				US 1992-849922 A	19920312
	AU 9335162	A1	19930916	AU 1993-35162	19930312
	AU 665059	B2	19951214		
				US 1992-849922 A	19920312
	CN 1096299	A	19941214	CN 1993-106796	19930608
				US 1992-849922	19920312
	US 5830864	A	19981103	US 1995-502981	19950717
				US 1992-849922	B219920312
				US 1993-25682	B119930303

OS MARPAT 120:271187
AB ABNHCH(CH2COR1)CONHCH(CR2R3CO2H)COD [A = R4NHCO; R4 = (unsatd.) alkyl, (substituted) phenylalkyl, alkylcycloalkyl; B = NHCHR5CO; R5 = 1-**tricyclo**[3.3.1.13,7]decyl, (substituted) alkyl; R1 = alkyl, cycloalkyl, amino; R2 = H, alkyl, R3 = alkyl; or R2 = H, R3 = phenylalkyl;

or R2R3C = cycloalkyl; D = NHR8; R8 = alkyl], were prepared Thus, Pr2CHNHCO-Tbg-Asp(pyrrolidino)-Asp(cyPn)-γMeLeucinal [Tbg = (S)-2-amino-3,3-dimethylbutanoate residue, γMeLeu = (S)-2-amino-4,4-dimethylpentanoate residue, Asp(cyPr) = (S)-γ-amino-1-carboxycyclopentaneacetate residue], prepared by solution phase reactions, inhibited Herpes simplex virus (HSV) ribonucleotide reductase with IC50 = 0.08 μM, and inhibited HSV replication in cell culture with EC50 = 75 μM. Title compds. act synergistically with antiviral nucleoside analogs.

L12 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:408173 CAPLUS
DN 119:8173
TI Molecular mechanical study of structure, strain, and conformation of alicyclic epoxides
AU Kas'yan, L. I.; Seferova, M. F.; Porubleva, L. V.
CS Dnepropetr. Gos. Univ., Dnepropetrovsk, Ukraine
SO Zhurnal Organicheskoi Khimii (1992), 28(3), 449-60
CODEN: ZORKAE; ISSN: 0514-7492
DT Journal
LA Russian
GI



I



II



III

AB The MM2 method was used to study epoxides of cyclic and bicyclic compds., e.g., I (n = 1, 2), II, and III (m = 1, 2, 3). Relations between strain energy and some geometric and physicochem. parameters were discussed.

L12 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:59575 CAPLUS
DN 118:59575
TI N-[[[(2-benzofuranyl)methyl]amino]alkyl]carboxamides, a method for their preparation and their use as antidepressants, antipsychotics and anxiolytics
IN Stack, Gary P.
PA American Home Products Corp., USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5134140	A	19920728	US 1991-719853	19910621
				US 1991-719853	19910621

OS CASREACT 118:59575; MARPAT 118:59575
GI



I

AB Certain N-[[[(2-benzofuranyl)methyl]amino]alkyl]carboxamides, such as derivs. of **tricyclo**[3.3.1.13,7]decane-1-carboxamide or 4-fluorobenzamide, are claimed; also claimed is 8-[2-[[(7-methoxy-2-benzofuranyl)methyl]amino]ethyl]-8-azaspiro[4.5]decane-7,9-dione (I). Methods for the treatment of psychoses, depression or anxiety are claimed which comprise the administration of said compds. I.HCl was prepared from 3,3-tetramethyleneglutaric anhydride and 2-[[(7-methoxy-2-benzofuranyl)methyl]amino]ethylamine. I had activity as a 5-HT1a-agonist.

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:632012 CAPLUS
DN 115:232012
TI Samarium diiodide promoted spirolactonization of cycloalkanones
AU Csuk, Rene; Hu, Zhong; Abdou, Mohamed; Kratky, Christoph
CS Pharm. Chem. Inst., Univ. Heidelberg, Heidelberg, D-W6900, Germany
SO Tetrahedron (1991), 47(34), 7037-44
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 115:232012
GI For diagram(s), see printed CA Issue.
AB The reaction of cycloalkanones with Me 3-bromopropionate and SmI2 afforded spiroannellated γ-lactones, e.g., I (n = 4-7), pinacols, and unprecedented hydroxycycloalkyloxaspiroalkanones II.

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:552342 CAPLUS
DN 113:152342
TI Response of 2-lithio-4,5-dihydrofuran - ketone adducts to acid catalysis
AU Paquette, Leo A.; Lawhorn, David E.; Teleha, Christopher A.
CS Evans Chem. Lab., Ohio State Univ., Columbus, OH, 43210, USA
SO Heterocycles (1990), 30(2, Spec. Issue), 765-9
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 113:152342
GI



I

II



III

AB Tert. allylic alcs. I [R1 = R2 = Me; R1R2 = (CH2)4, CH2CH2OCH2CH2, adamantyl, etc.] cyclodimerized to spirodioxanes or rearranged to ring-expanded spirocyclic ketones. E.g., the treatment of I [R1R2 = (CH2)4] with Dowex-50X gave 71% spirocyclic ketone II, while treatment of I (R1R2 = CH2CH2OCH2CH2) with 4-MeC6H4SO3H gave spirodioxane III.

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:594168 CAPLUS
DN 111:194168
TI A simple iterative approach to the synthesis of cis-cisoid-cis-**tricyclo**[6.3.0.02,6]undecane carbon skeleton
AU Vankar, Padma S.; Chandrasekaran, Srinivasan
CS Dep. Chem., Indian Inst. Technol., Kanpur, 208016, India
SO Bulletin of the Chemical Society of Japan (1989), 62(4), 1388-9
CODEN: BCSJA8; ISSN: 0009-2673
DT Journal
LA English
OS CASREACT 111:194168
GI



I

AB In an iterative synthesis utilizing only four reagents, cyclopentanone has been converted into cis-cisoid-cis-**tricyclo**[6.3.0.02,6]undecane I in high yield. Thus, iterative treatment of cyclopentanone with BrMgCH2CH2CH:CH2, hexadecyltrimethylammonium permanganate, P2O5/MeSO3H, and catalytic hydrogenation gave I.

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:7169 CAPLUS
DN 110:7169
TI Site-selective oxidation of saturated hydrocarbons by intramolecular reactions
AU Saito, Isao; Mano, Takashi; Nagata, Ryu; Uematsu, Nobuyuki; Matsuura, Teruo
CS Fac. Eng., Kyoto Univ., Kyoto, 606, Japan
SO Studies in Organic Chemistry (Amsterdam) (1988), 33(Role Oxygen Chem. Biochem.), 73-8
CODEN: SOCHDQ; ISSN: 0165-3253
DT Journal
LA English
GI

$CMe(OOBz)OSiMe_2CMe_3$ I

AB A novel oxidation method utilizing silyl-protected peroxy ester I and $Fe(ClO_4)_3$ has been devised for the oxidation of saturated hydrocarbons. Regioselective oxidation of an alkyl chain and a steroidal skeleton is accomplished by the intramol. version of this method.

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1965:462789 CAPLUS
DN 63:62789
OREF 63:11450f-h
TI Perhydroindan derivatives. V. The synthesis of some 3a-substituted derivatives
AU House, Herbert O.; Boots, Sharon G.; Jones, Vera K.
CS Massachusetts Inst. of Technol., Cambridge
SO Journal of Organic Chemistry (1965), 30(8), 2519-27
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 63:62789
GI For diagram(s), see printed CA Issue.
AB cf. CA 60, 6800c. Several model compounds for ring closure studies have been prepared including 3a-carbomethoxymethyl-5-oxo-cis-perhydroindan, 3a-acetyl-5-oxo-cis-perhydroindan, and the epoxide of methyl 3-methylenecyclohexylacetate. The diazo ketones I and II were converted to the corresponding cyclopropyl ketones III and IV and the reactions of these cyclopropyl ketones with hydrogen bromide and with lithium in ammonia were studied. Application of the Arndt-Eistert reaction to I yielded, in addition to the expected product V, the cyclopropyl ketone III and two cyclobutanone derivatives VI and VII.

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1960:6778 CAPLUS
DN 54:6778
OREF 54:1364e-i
TI Substituted γ-butyrolactones
IN Sanne, Walter
PA Badische Anilin- & Soda-Fabrik Akt.-Ges.

DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1018856		19571107	DE	

GI For diagram(s), see printed CA Issue.
AB Substituted succinic acid anhydrides were hydrogenated in the presence of organic solvents and of catalysts at elevated temps. to give the title compds., useful as intermediates in the manufacture of pesticides and pharmaceuticals. Thus, 200 g. maleic acid anhydride adduct of cyclooctatetraene (I), 300 g. dioxane, and 20 g. Raney Ni was hydrogenated 3 hrs. at 180°/150 atmospheric in a stirring autoclave, the catalyst separated, the solvent removed, and the residue distilled to give the lactone of 2-hydroxymethyl **tricyclo**[2.2.4.07,10]decane-3-carboxylic acid of the formula II (X = CO, Y = CH2), b15 195°, m. 113-14°. I in cyclohexane hydrogenated 3 hrs. at 260°/200 atmospheric in the presence of Raney Ni gave II, b0.2 120-5°, besides a tetrahydrofuran derivative of the formula II (X = Y = CH2), b0.8 84-6°. I in dioxane hydrogenated 8 hrs. at 40°/200 atmospheric in the presence of Raney Ni gave II (X = CO, Y = CH2) besides the hydrogenated starting compound of the formula II (X = Y = CO), m. 143-4°. α,α-Heptamethylenesuccinic acid anhydride in dioxane hydrogenated in the presence of Raney Ni 4 hrs. at 260°/150 atmospheric gave mixed α,α-heptamethylenebutyrolactone and β,β-heptamethylenebutyrolactone, b0.1 92-4°, besides β,β-heptamethylenetetrahydrofuran, b0.2 80-4°. α-Methyl-α-phenylsuccinic acid anhydride in dioxane hydrogenated in the presence of Raney Ni 3 hrs. at 180°/200 atmospheric gave mixed α-methyl-α-phenyl- and β-methyl-β-phenylbutyrolactones, b0.1 89-91°.

```
=> s oxaspiro and decan
L13         139 OXASPIRO AND DECAN

=> s l13 and one
L14         127 L13 AND ONE

=> s oxaspiro and nonan
L15          85 OXASPIRO AND NONAN

=> s l15 and one
L16          82 L15 AND ONE

=> s l14 and l16
L17          34 L14 AND L16

=> s l17 and tricyclo
L18           1 L17 AND TRICYCLO

=> s l17 and bicyclo
L19           1 L17 AND BICYCLO

=> s l17 fbib hitstr abs total
MISSING OPERATOR L17 FBIB
The search profile that was entered contains terms or
```

nested terms that are not separated by a logical operator.

=> d l17 fbib hitstr abs total

L17 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:335101 CAPLUS
DN 138:353836
TI Preparation of 4-[(2-furoyl)amino]piperidine derivatives and intermediates as inhibitors of side effects of opioid μ receptor agonists
IN Fukutomi, Ryuuta; Inoue, Hitoshi; Kawamura, Koji; Kishimoto, Takuya; Suzuki, Masashi; Shibayama, Rie; Kojima, Kazuko; Hagihara, Kouichirou
PA Kyorin Pharmaceutical Co., Ltd., Japan; Nisshin Pharma Inc.
SO PCT Int. Appl., 295 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003035645	A1	20030501	WO 2002-JP10449	20021008

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2001-311828 A 20011009

OS MARPAT 138:353836
GI



I



II

AB The title compds. I [wherein X = CH or N; Y = H or (un)substituted alkyl;

Z = H or furoyl] and pharmaceutically acceptable salts are prepared For example, the compound II was prepared in a multi-step synthesis. I are useful in preventing or treating side effects of opioid μ receptor agonists selected from among constipation, nausea, vomiting, itching, postoperative ileus, paralytic ileus, irritable bowel syndrome, or chronic itching (no data). I showed antagonist activity with pA2 of 7.85 to 8.86 against opioid μ receptor in guinea pig. Formulations containing I as an active ingredient were also described.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539676 CAPLUS
DN 137:93693
TI Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidineacetamides and piperidineacetamides and related compounds as MMP, TNF, and/or aggrecanase inhibitors
IN Chen, Xiao-Tao; Xue, Chu-Biao
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055516	A2	20020718	WO 2002-US761	20020109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-260952PP	20010111
US 2002137734	A1	20020926	US 2002-43627	20020109
			US 2001-260952PP	20010111
EP 1355901	A2	20031029	EP 2002-714734	20020109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-260952PP	20010111
			WO 2002-US761 W	20020109

OS MARPAT 137:93693
GI



I



II

AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cycle; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl),, CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SO0-2, or CO; Za = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R2a and R2b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR2aR2b = heterocyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the N-hydroxy-2-(quinolinylmethoxyphenylsulfonyl methyl)-2-pyrrolidineacetamide II•2CF3CO2H was prepared in twelve steps starting with the esterification of N-Boc-proline using MeI and K2CO3 in acetone. Key steps include the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds. exhibited Ki values of ≤ 10 μM against MMP-1, 2, 3, 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).

L17 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:321295 CAPLUS
DN 135:92230

TI A detailed ab initio MO investigation of the diastereoselectivities of five- and six-membered ring ketones bearing O and S, C and S, and C and O substituents at the α-carbon
AU Yadav, V. K.; Sriramurthy, V.
CS Department of Chemistry, Indian Institute of Technology, Kanpur, 208 016, India
SO Tetrahedron (2001), 57(18), 3987-3995
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
AB The steric effects in the geometry on cation-chelation predict the exptl. π-selectivity of 1-oxa-4-thiaspiro[4.5] **decan**-6-**one**, 1-oxa-4-thiaspiro[4.4]**nonan**-6-**one**, 1-thiaspiro[4.4] **nonan**-6-**one**, and 1-**oxaspiro**[4.4]**nonan** -6-**one**. The reversal in the selectivity of 1-oxa-4-thiaspiro[4.4]**nonan**-6-**one** on reduction with (i-Bu)2AlH appears to be a direct consequence of the steric interactions arising from the large i-Bu substituents. The antiperiplanar effects are not as significant as the steric effects. An ab initio MO investigation of the diastereoselectivities five- and six-membered ring ketones bearing O and S, C and S, and C and O substituents with the application of the cation-complexation model is described.
RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:167218 CAPLUS
DN 135:19208
TI Alkoxy radical accelerated β-fragmentation of alcohols and lactols
AU Rigby, J. H.; Payen, A.; Warshakoon, N.
CS Department of Chemistry, Wayne State University, Detroit, MI, 48202, USA
SO Tetrahedron Letters (2001), 42(11), 2047-2049
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 135:19208
AB Treatment of alcs. and lactols with Pb(OAc)4/Cu(OAc)2 in refluxing benzene provides the corresponding δ-unsatd. carbonyl products.
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:44773 CAPLUS
DN 134:252253
TI Asymmetric Baeyer-Villiger Oxidations of 4-Mono- and 4,4-Disubstituted Cyclohexanones by Whole Cells of Engineered Escherichia coli
AU Mihovilovic, Marko D.; Chen, Gang; Wang, Shaozhao; Kyte, Brian; Rochon, Fernande; Kayser, Margaret M.; Stewart, Jon D.
CS Departments of Chemistry, University of New Brunswick, Saint John, NB, E2L 4L5, Can.
SO Journal of Organic Chemistry (2001), 66(3), 733-738
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English

OS CASREACT 134:252253
AB Whole cells of an Escherichia coli strain that overexpresses Acinetobacter sp. NCIB 9871 cyclohexanone monooxygenase have been used for the Baeyer-Villiger oxidns. of a variety of 4-mono- and 4,4-disubstituted cyclohexanones. In cases where comparisons were possible, this new biocatalytic reagent provided lactones with chemical yields and optical purities that were comparable to those obtained from the purified enzyme or a strain of bakers' yeast that expresses the same enzyme. The efficient production of cyclohexanone monooxygenase in the E. coli expression system (ca. 30% of total soluble protein) allowed these oxidns. to reach completion in approx. half the time required for the engineered bakers' yeast strain. Surprisingly, 4,4-disubstituted cyclohexanones were also accepted by the enzyme, and the enantioselectivities of these oxidns. could be rationalized by considering the conformational energies of bound substrates along with the enzyme's intrinsic enantioselectivity. The enzyme expressed in E. coli cells also oxidized several 4-substituted cyclohexanones bearing polar substituents, often with high enantioselectivities. In the case of 4-iodocyclohexanone, the lactone was obtained in >98% ee and its absolute configuration was assigned by X-ray crystallog. Taken together, these results demonstrate the utility of an engineered bacterial strain in delivering useful chiral building blocks in an exptl. simple manner.
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:753968 CAPLUS
DN 130:138978
TI Conversion of spirolactones to enones over Zeolite Y: a computational study
AU Chatterjee, A.; Vetrivel, R.; Sreekumar, R.; Murthy, Y. V. S. N.; Pillai, C. N.
CS Catalysis Division, National Chemical Laboratory, Pune, 411 008, India
SO Catalysis: Modern Trends, [Papers presented at the National Symposium on Catalysis], 12th Bombay, Dec. 19-22, 1994 (1996), Meeting Date 1994, 68-71. Editor(s): Gupta, N. M.; Chakrabarty, Dipak K. Publisher: Narosa, New Delhi, India.
CODEN: 66ZZAC
DT Conference
LA English
AB Various zeolites were reported as catalysts for the conversion of spirolactones to polycyclic enones. Computer-simulation techniques such as computer graphics, force-field calcns. and mol. fitting were used for understanding this novel reaction in HY. Force-field calcns. adopted for the mols. involved in the reaction indicate the geometry and conformational flexibility of these mols. Possible orientations of the reactant and product mols. in the 12-member window to the super cage of Zeolite Y as well as fitting of these mols. were tried.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:584726 CAPLUS
DN 129:290028
TI A new coupling reaction between β-lactones and electrophiles mediated by a SmI2/(NiI2 catalytic) system
AU Machrouhi, Fouzia; Namy, Jean-Louis

CS Laboratoire des Reactions Organiques Selectives, Institut de Chimie Moleculaire d'Orsay, associe au CNRS, Universite Paris-Sud, Orsay, 91405, Fr.
SO Tetrahedron (1998), 54(37), 11111-11122
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 129:290028
GI


I


II

AB β-Lactones react with ketones, aldehydes, and imines in the presence of a SmI2/(NiI2 catalytic) system to afford substituted tetrahydrofuranones and pyrrolidinones. For example. reaction of β-propiolactone (I) with cyclohexanone in THF containing SmI2 and NiI2 at room temp for 60 min gave, after acid catalyzed hydrolysis, the **oxaspiro**[4.5]decanone II.
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:450866 CAPLUS
DN 129:161483
TI Spiro γ-lactones via aluminum enolate-spiro epoxide openings
AU Taylor, Stephen K.; Chmiel, Nikolas H.; Mann, Emily E.; Silver, Michael E.; Vyvyan, James R.
CS Department Chemistry, Hope College, Holland, MI, 49422, USA
SO Synthesis (1998), (7), 1009-1014
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 129:161483
AB The opening of several spiro epoxides by Al ester enolates is described. The isolated γ-hydroxy esters are cyclized to the corresponding spiro lactones with high efficiency. Alternatively, the crude product from epoxide opening may be directly converted to the spiro lactone without purification of the intermediate hydroxy ester. This methodol. provides another complementary route to 1-**oxaspiro**[4.n]-2-**one** systems that are of structural and biol. interest.

L17 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:168206 CAPLUS
DN 128:257069
TI Computer simulation study on the conversion of spirolactone to enones over H-Y zeolite
AU Chatterjee, A.; Iwasaki, T.; Ebina, T.; Vetrivel, R.
CS Inorganic Material Section, Tohoku National Industrial Research Institute, AIST, Sendai, 983, Japan

SO Journal of Molecular Graphics & Modelling (1998), Volume Date 1997, 15(4), 216-220, 259
CODEN: JMGMFI; ISSN: 1093-3263
PB Elsevier Science Inc.
DT Journal
LA English
AB We report here the results of computer modeling studies and quantum chemical calcns. on the spirolactone-to-enone conversion reaction over the zeolite catalysts, especially H-Y zeolite. We studied the adsorption mode of the mols. inside the supercage of H-Y and the mechanism of electron transfer between organic mols. and the framework of zeolite H-Y by d. functional theory (DFT) calcns. Because the organic mols. considered in the present study are less sym. we docked the mol. inside the supercage of H-Y and energy minimization was then applied to these docked structures to yield representative low-energy binding sites for the mols. within the host structure. The interaction energy results show that the major interaction is between the methylene hydrogen of the mol. and the oxygen of the framework. The mol. electrostatic potential maps show that the ketonic oxygen of the reactant mols. abstract proton from Bronsted acid site. Thus the mechanism proposed by DFT calcn. matches well with the exptl. observations.
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:811848 CAPLUS
DN 128:127658
TI The structural fitting and the interaction energy between the zeolite lattice models and organic molecules in the conversion of spirolactones to enones
AU Chatterjee, A.; Vetrivel, R.; Sreekumar, R.; Murthy, Y. V. S. N.; Pillai, C. N.
CS Nigatake, AIST, Inorganic Material Section, Tohoku National Industrial Research Institute, Miyagino-ku, Sendai 983, 4-2-1, Japan
SO Journal of Molecular Catalysis A: Chemical (1997), 127(1-3), 153-162
CODEN: JMCCF2; ISSN: 1381-1169
PB Elsevier Science B.V.
DT Journal
LA English
AB We report here the results of our modeling studies and cluster calcns. on the spirolactone to enone conversion reaction over zeolite catalysts. The structural role and the interaction energy introduced by the zeolite framework in this reaction are studied. The shape selective catalytic behavior of various zeolites are rationalized by comparing the dimension of the mols. and zeolite pore diameter It is observed that the spirolactone and enone mols. have dynamic freedom to hop among the various sites inside the supercage of zeolite-Y. The abstraction of proton at Bronsted acid site by ketonic oxygen of the reactant has been indicated as the first step in the reaction mechanism. The interaction energy of the mols. with the framework cluster and the electron redistribution occurring in the reactant mols. due to adsorption are discussed. These results are useful to understand the mechanism of the dehydration of spirolactones to form enones.
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:533418 CAPLUS
DN 127:220400
TI Synthesis and applications of tetrahydrofuran-stable substituted (3-lithioxyalkyl)- and (4-lithioxyalkyl)lithiums, modified with magnesium 2-ethoxyethoxide
AU Kostas, Ioannis D.; Screttas, Constantinos G.
CS Natl. Hellenic Res. Foundation, Inst. Org. Pharm. Chem., Athens, 116 35, Greece
SO Journal of Organic Chemistry (1997), 62(16), 5575-5577
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 127:220400
AB HOCR1R2(CH2)nCH2CH2SPh [I, R1R2 = (CH2)m, m = 4-7; n = 0, 1] have been synthesized from HOCR1R2(CH2)nCH:CH2. Regiospecific cleavage of the C-SPh bond of I by lithium dispersion in THF led to substituted (3-lithioxyalkyl)- and (4-lithioxyalkyl)lithiums, most of which share the ω carbon with a carbocyclic ring. The organolithiums were modified with magnesium 2-ethoxyethoxide in order to suppress their reactivity toward THF cleavage, thus offering the advantage of preparing storable ethereal solution of certain types of (lithioxyalkyl)lithiums. This strategy appears to be of rather broad scope. The functionalized organolithiums prepared in this way react normally with electrophilic reagents with yields in the range 35-55%. Thus, carboxylations yielded lactones, some of which are natural products, while reactions with benzophenone and cyclic ketones yielded 1,4- and 1,5-diols.
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:484646 CAPLUS
DN 125:247962
TI 1,5-Ph3Ge and 1,6-Bu3Sn group transfer from enoxy oxygen to alkoxy oxygen
AU Kim, Sunggak; Do, Jung Yun; Lim, Kwang Min
CS Dep. Chem., Korea Adv. Inst. Sci. Technol., Taejon, 305-701, S. Korea
SO Chemistry Letters (1996), (8), 669-670
CODEN: CMLTAG; ISSN: 0366-7022
PB Nippon Kagakkai
DT Journal
LA English
OS CASREACT 125:247962
GI



I



II



III



IV

AB 1,5-Ph3Ge and 1,6-Bu3Sn group transfer from enoxy O to alkoxy O are observed in radical reaction of keto epoxides and keto oxetanes, resp. E.g., reaction of keto epoxide I (n = 3, R1 = R2 = H) with Ph3GeD/AIBN in refluxing benzene gave adduct II in 91% yield, while keto oxetane III (n = 2) reacted with Bu3SnD/AIBN under same conditions to give IV in approx. 81% yield.

L17 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:474775 CAPLUS
DN 125:195314
TI Palladium(II)-catalyzed formation of γ-butyrolactones from 4-trimethylsilyl-3-alkyn-1-ols: synthetic and mechanistic aspects
AU Compain, Philippe; Gore, Jacques; Vatele, Jean-Michel
CS Lab. Chimie Organique I, Univ. Claude Bernard, Villeurbanne, 69622, Fr.
SO Tetrahedron (1996), 52(31), 10405-10416
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
OS CASREACT 125:195314
AB γ-Butyrolactones are obtained in good yields from 4-trimethylsilyl-3-alkyn-1-ols via Wacker-type oxidation reaction. A mechanism is proposed for this transformation: it involves two successive trans-hydroxypalladations followed by a [PdXSiMe3] syn-elimination and explains why the presence of the silyl group is essential in such a process.

L17 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:695076 CAPLUS
DN 123:339570
TI A new synthesis of lactones from tertiary alkenylcarbinols by cobalt-catalyzed photocarbonylation under ambient conditions
AU Chow, Yuan L.; Huang, Yu-Jin; Dragojlovic, Veljko
CS Dep. Chem., Simon Fraser Univ., Burnaby, BC, B5A 1S6, Can.
SO Canadian Journal of Chemistry (1995), 73(5), 740-2
CODEN: CJCHAG; ISSN: 0008-4042
PB National Research Council of Canada
DT Journal

LA English
OS CASREACT 123:339570
AB In the presence of a Co catalyst, tertiary vinyl-, propenyl-, and allylcarbinols ere chelatively cycloadded to carbon monoxide to produce lactones by xanthone-sensitized photoreaction in THF, under CO at 1 atm and at room temperature At lower temps., the isomerization of alkenyl-carbinols was suppressed and lactones were obtained with improved selectivity. The photoprocess was facilitated by addition of pyridine or hydrogen and retarded in the presence of amines or phosphines. Mechanistic interpretations for the process and the accompanying effects are discussed.

L17 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:678965 CAPLUS
DN 123:313726
TI Improved enantioselection for chiral dirhodium(II) carboxamide-catalyzed carbon-hydrogen insertion reactions of tertiary alkyl diazoacetates
AU Doyle, Michael P.; Zhou, Qi-Lin; Raab, Conrad E.; Roos, Gregory H. P.
CS Dep. Chem., Trinity Univ., San Antonio, TX, 78212, USA
SO Tetrahedron Letters (1995), 36(27), 4745-8
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 123:313726
AB Enantiocontrol in C-H insertion reactions of 3° alkyl diazoacetates, which is highly dependent on the catalyst ligand, is greatly enhanced with the use of dirhodium(II) catalysts such as tetrakis[methyl 1-acetylimidazolidin-2-**one**-4(S)-carboxylate], RH2(4S-MACIM)4. Thus, [(1-acetyl-2-oxo-4-imidazolidinecarboxylato-N3:O2)]dirhodium-catalyzed insertion reaction of diazoacetic acid 1-methylcyclopentyl ester gave cis-(-)-hexahydro-6a-methyl-2H-cyclopenta[b]furan-2-**one** and 1-**oxaspiro**[4.4] **nonan**-2-**one** in a 90:10 ratio in 85% overall yield. A similar product ratio was observed in the [(2-oxo-4-oxazolidinedinecarboxylato-N3:O2)]dirhodium-catalyzed insertion reaction.

L17 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:553885 CAPLUS
DN 122:314442
TI Spirolactones from Dirhodium(II)-Catalyzed Diazo Decomposition with Regioselective Carbon-Hydrogen Insertion
AU Doyle, Michael P.; Dyatkin, Alexey B.
CS Department of Chemistry, Trinity University, San Antonio, TX, 78212, USA
SO Journal of Organic Chemistry (1995), 60(10), 3035-8
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 122:314442
GI



I



II

AB Dirhodium(II) caprolactamate, Rh2(cap)4, catalyzes diazo decomposition of cycloalkylmethyl diazoacetates, e.g., I, which form spirolactones, e.g., II, in moderate to high yield by insertion into a tertiary carbon-hydrogen bond. Similar results are obtained with diazoacetates derived from tetrahydropyran-2-methanol and tetrahydrofurfuryl alc. but not from cyclopropylmethanol. With tetrahydrofuran-3-ylmethyl diazoacetate, Rh2(cap)4 catalysis promotes δ-lactone formation via insertion into the oxygen-activated secondary C-H bond instead of γ-lactone formation by carbene insertion into the unactivated tertiary C-H bond. However, when both 1,5- and 1,6-positions are activated for insertion by adjacent oxygen atoms, as in (2,2-dimethyl-1,3-dioxolan-4-yl)methyl diazoacetate, five-membered ring formation occurs exclusively in Rh2(cap)4-catalyzed reactions, whereas use of dirhodium(II) acetate leads to both insertion products.

L17 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:270819 CAPLUS
DN 123:198598
TI A new synthesis of γ-butyrolactones via palladium(II)-catalyzed cyclization of trimethylsilylalkynes
AU Compain, Philippe; Vatele, Jean-Michel; Gore, Jacques
CS Laboratoire Chimie Organique 1, Universite Claude Bernard, Villeurbanne, 69622, Fr.
SO Synlett (1994), (11), 943-5
CODEN: SYNLES; ISSN: 0936-5214
PB Thieme
DT Journal
LA English
OS CASREACT 123:198598
AB In the presence of CuCl2 and O2, palladium(II)-catalyzed cyclization of 1-substituted 4-(trimethylsilyl)-3-butyn-1-ols gave γ-butyrolactones in satisfactory yields (50-74%). The effect of exptl. parameters on the yield and on the reaction time was studied. The best results were obtained by using Pd(OAc)2 or PdClNO2(CH3CN)2 as catalysts and a mixture of CH3CN and 1N HCl as solvent. The palladium-catalyzed cyclization of (S)-α-[3-(trimethylsilyl)-2-propyn-1-yl]benzenemethanol gave (S)-dihydro-5-phenyl-2(3H)furanone (58% yield, >98% enantiomeric excess).

L17 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:269985 CAPLUS
DN 120:269985
TI Thionium ion-activated pinacol rearrangements. Generality and scope
AU Paquette, Leo A.; Dullweber, Uta; Branan, Bruce M.
CS Evans Chem. Lab., Ohio State Univ., Columbus, OH, 43210, USA
SO Heterocycles (1994), 37(1), 187-91
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
GI



AB The acid-catalyzed rearrangement of tertiary allylic alcs. I (n = 3, 4, 5, 7, 11), produced by the addition of 5-lithio-2,3-dihydrothiophene to cyclic ketones of various ring size, has been probed. Thus, I (n = 4) rearranged to spirothiophene II.

L17 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:560069 CAPLUS
DN 119:160069
TI Radical cyclizations of diosphenol ω-haloalkyl ethers to oxabicycloalkanones
AU Ponaras, Anthony A.; Zaim, Omer
CS Dep. Chem., Cathol. Univ. America, Washington, DC, 20064, USA
SO Tetrahedron Letters (1993), 34(18), 2879-82
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
GI



AB Radical cyclization of diosphenol ω-haloalkyl ethers gives spiro- and fused oxabicycloalkanones. Thus, (bomopropoxy)cyclohexenone I (R = Br) was treated with Bu3SnH in C6H6 to give 33 and 7% the trans- and cis-oxabicyclodecanones II, 47% the spirocyclic ketone III, and less than 2% I (R = H). A number of analogous cyclizations were studied and factors affecting the regiochem. and amount of cyclization vs. reduction are discussed.

L17 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:449159 CAPLUS
DN 119:49159
TI Samarium trichloride-catalyzed electrosynthesis of γ-butyrolactones from 3-chloro esters and carbonyl compounds
AU Hebri, Hassan; Dunach, Elisbet; Perichon, Jacques
CS Lab. Electrochim., CNRS, Thiais, 94320, Fr.
SO Journal of the Chemical Society, Chemical Communications (1993), (6), 499-500
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
OS CASREACT 119:49159
GI



AB Electrosynthesis of γ-butyrolactones I [R1R2 = (CH2)5, (CH2)4; R1 = n-C6H13, R2 = Me, H; R1 = PhCH2CH2, R2 = Me;, etc.] has been achieved by the direct reductive coupling of Et 3-chloropropionate and R1R2CO in the presence of a catalytic amount of SmCl3.

L17 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:651152 CAPLUS
DN 117:251152
TI Substituent-directed oxidative cyclization of γ-hydroxy olefins to γ-lactones with hexavalent chromium reagents
AU Baskaran, Sundarababu; Islam, Imadul; Chandrasekaran, Srinivasan
CS Dep. Org. Chem., Indian Inst. Sci., Bangalore, 560 012, India
SO Journal of Chemical Research, Synopses (1992), (8), 290
CODEN: JRPSDC; ISSN: 0308-2342
DT Journal
LA English
GI



II

AB The oxidative cyclization of RR1CH(OH)CH2CH2CH:CR2R3 [I; R = Me, Ph, PhCH2; R1 = Me; RR1 = (CH2)n, n = 4, 5; R3, R4 = H, Me] to γ-lactones II with oxo-chromium(VI) reagents such as pyridinium chlorochromate or pyridinium dichromate was studied. The reaction is believed to proceed via the formation of a chromium ester which decomps. to give II. The mode of decomposition of the chromium ester appear to depend on the nature of the substitution of the I.

L17 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:531398 CAPLUS
DN 117:131398
TI A general methodology for the synthesis of linearly fused polyquinanes.
AU Murthy, Y. V. Suryanarayana; Pillai, C. Narayana
CS Dep. Chem., Indian Inst. Technol., Madras, 600 036, India
SO Tetrahedron (1992), 48(25), 5331-46
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 117:131398
GI



I



II



III



IV

AB A methodol. involving a combination of spiro-annulation by the action of 1,4-dibromomagnesiobutane on succinic acid derivs. followed by cyclization of the spirolactone using P2O5-CH3SO3H reagent was developed for the synthesis of polyquinanes. By using bicyclo[2.2.1]heptanecarboxylic acids I and II as the precursors for the spirolactones, triquinane III and pentaquinane IV were synthesized.

L17 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:632012 CAPLUS
DN 115:232012
TI Samarium diiodide promoted spirolactonization of cycloalkanones
AU Csuk, Rene; Hu, Zhong; Abdou, Mohamed; Kratky, Christoph
CS Pharm. Chem. Inst., Univ. Heidelberg, Heidelberg, D-W6900, Germany
SO Tetrahedron (1991), 47(34), 7037-44
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 115:232012
GI For diagram(s), see printed CA Issue.
AB The reaction of cycloalkanones with Me 3-bromopropionate and SmI2 afforded spiroannellated γ-lactones, e.g., I (n = 4-7), pinacols, and unprecedented hydroxycycloalkyloxaspiroalkanones II.

L17 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:429023 CAPLUS
DN 115:29023
TI Belted spirocyclic tetrahydrofurans - a new class of preorganized ionophoric polyethers. Molecular structure, conformation, and binding to alkali metal atoms
AU Negri, Joanna T.; Rogers, Robin D.; Paquette, Leo A.
CS Evans Chem. Lab., Ohio State Univ., Columbus, OH, 43210, USA
SO Journal of the American Chemical Society (1991), 113(13), 5073-5
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CASREACT 115:29023
GI


I


II


III


IV


V

AB The preparation and ionophoric properties of spirocyclic tetrahydrofurans I-V are described. The syntheses make use of α-heteroatom substitution to effect ring closure by the newly discovered associative SN reaction. The ground-state conformational preferences of the trispiro esters, established by x-ray crystallog., reflect the thermodn. importance of gauche C-O/C-O sigma bond interactions. The coordinative abilities of the ionophores toward alkali metal ions are respectable despite a relatively limited number of binding sites.

L17 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:429019 CAPLUS
DN 115:29019
TI A **one**-pot synthesis of racemic and enantiomeric γ-butyrolactones
AU Mandal, Arun K.; Mahajan, S. W.
CS Alchem. Res. Cent., Maharashtra, 400 601, India
SO Synthesis (1991), (4), 311-13
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
OS CASREACT 115:29019
GI


I


II


III

AB Borinate esters, e.g. I, derived from the hydroboration of homoallylic alcs. HOCR2CR12CHR2CH:CH2 [R = Et, R1 = R2 = H; 2R = (CH2)5, R1 = Me, R2 = H, R1 = H, R2 = Me; 2R = (CH2)n, R1 = R2 = H, n = 4-7] and (R)-HOCHR3CH2CH:CH2 (R3 = Me, Et) were oxidized with chromic acid to provide a **one**-pot synthesis of the racemic and enantiomeric γ-butyrolactones (2-oxotetrahydrofurans) II and III.

L17 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:121879 CAPLUS
DN 114:121879
TI The key role of water in the heterogeneous permanganate oxidation of ω-hydroxy alkenes
AU Baskaran, Sundarababu; Islam, Imadul; Vankar, Padma S.; Chandrasekaran, Srinivasan
CS Dep. Org. Chem., Indian Inst. Sci., Bangalore, 560 012, India
SO Journal of the Chemical Society, Chemical Communications (1990), (23), 1670-1
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
OS CASREACT 114:121879
AB KMnO4-CuSO4 in CH2Cl2 containing a catalytic amount of H2O effects a smooth oxidative cyclization of ω-hydroxy alkenes to ω-lactones in good yields with the net loss of ≥1 C atoms in the process.

L17 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:514968 CAPLUS
DN 113:114968
TI Oxidation of tetrahydrofuranmethanol derivatives with pyridinium chlorochromate: a facile synthesis of γ-butyrolactones
AU Baskaran, S.; Chandrasekaran, S.
CS Dep. Org. Chem., Indian Inst. Sci., Bangalore, 560 012, India
SO Tetrahedron Letters (1990), 31(19), 2775-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 113:114968
AB Treatment of a number of tetrahydrofuranmethanol derivs. with pyridinium chlorochromate led to the formation of the corresponding γ-butyrolactones with the loss of **one** or more carbon atoms in good yields under mild reaction conditions.

L17 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:76663 CAPLUS
DN 112:76663
TI A general approach to the synthesis of butanolides: synthesis of the sex pheromone of the Japanese beetle
AU Baskaran, Sundarababu; Islam, Imadul; Chandrasekaran, Srinivasan
CS Dep. Chem., Indian Inst. Technol., Kanpur, 208 016, India
SO Journal of Organic Chemistry (1990), 55(3), 891-5
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 112:76663
GI



AB Me2C:CHCH2CH2CRR1OH (R = vinyl, allyl, C.tplbond.CH, Et, CH2Ph, Ph, hexyl, R1 = Me; R = decynyl, R1 = H) and some related compds. were converted to butanolides I in very high yield via bromoetherification, elimination, and oxidative cleavage. The key step is the highly selective oxidative cleavage of enol ethers II with pyridinium chlorochromate under mild reaction conditions. The Japanese beetle pheromone, I [R = (Z)-decenyl, R1 = H] was prepared from I (R = decynyl, R1 = H).

L17 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:477910 CAPLUS
DN 111:77910
TI Carbon-carbon bond cleavage of 2-acylimidazolium salts in a sequence involving a new ester homoenolate equivalent. A synthesis of γ-lactones
AU Davies, D. Huw; Hall, Jonathan; Smith, Edward H.
CS ICI Pharm., Macclesfield/Cheshire, SK10 4TG, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1989), (4), 837-8
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 111:77910
GI



AB Reaction of the anion of 2-[1-(triisopropylsiloxy)allyl]-N-(methoxymethyl)imidazole with ketones and aldehydes proceeds regioselectivity to give silyl enol ethers I (R = Ph, CHMe2, R1 = H; R = Me, R1 = Me, CH2CHMe2; etc.) which are cleaved to γ-lactones II (same R, R1) after desilylation, N-methylation, and base treatment.

L17 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:212154 CAPLUS
DN 110:212154
TI The chemistry of small-ring compounds. Part 51. Electron-transfer-initiated oxidation of some cyclopropylidene compounds
AU Hofland, A.; De Boer, T. J.
CS Lab. Org. Chem., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.
SO Recueil des Travaux Chimiques des Pays-Bas (1987), 106(11), 558-62
CODEN: RTCPA3; ISSN: 0165-0513
DT Journal
LA English

OS CASREACT 110:212154
GI


I

II

III

AB Cyclopropylidene compds. I, II, and III quench the fluorescence of 9,10-dicyanoanthracene (DCA). Nevertheless, photooxygenation in the presence of DCA does not give dioxetanes but (in MeOH) leads to a methoxy hydroperoxide, which undergoes acid rearrangement to a lactone or to a cyclobutanone, depending on the reaction conditions.

L17 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:38772 CAPLUS
DN 110:38772
TI Synthesis of γ-lactones by hydroboration-oxidation of homoallylic alcohols
AU Nguyen Cong Hao; Mavrov, M. V.; Chrelashvili, Z. G.; Serebryakov, E. P.
CS Inst. Org. Khim. im. Zelinskogo, Moscow, USSR
SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1988), (5), 1184-6
CODEN: IASKA6; ISSN: 0002-3353
DT Journal
LA Russian
OS CASREACT 110:38772
GI



I


II


III

AB **One**-pot hydroboration of tertiary homoallylic alcs., e.g., I (n = 1,2), and then oxidation of the resulting organoboranes with chromic acid gave 60% γ-lactones, e.g., II (n = 1,2). Extension of this method to EtCH:CHCHMeOAc gave 4-hexanolide (III), a component of the aggregation pheromone of skin beetles.

L17 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:39882 CAPLUS
DN 58:39882
OREF 58:6765e-g
TI Spirans. V. Diastereoisomeric grisenones obtained by oxidative cyclization
AU Dean, F. M.; Locksley, H. D.
CS Univ. Liverpool, UK
SO Journal of the Chemical Society, Abstracts (1963) 393-401
CODEN: JCSAAZ; ISSN: 0590-9791
DT Journal

LA Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 58, 2425b. Both (racemic) diastereoisomers of 4,5:2',3'-dibenzo-3-phenylgrisa-2',4'-dien-6'-**one** (I) have been made by oxidative cyclization of benzaldi-β-naphthol (1,1'-benzylidenedi-2-naphthol) and have been assigned configurations by three methods. The discussion includes brief comments on the stereochemistry of the catechins and on the synthesis of unsym. xanthenes.

L17 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:39881 CAPLUS
DN 58:39881
OREF 58:6765b-e
TI Primary-secondary and primary-tertiary acetylenic glycols
AU Vartanyan, S. A.; Chukhadzhyan, G. A.; Melikyan, R. A.; Babanyan, Sh. A.
SO Izvestiya Akademii Nauk Armyanskoi SSR, Khimicheskie Nauki (1962), 15, 45-51
CODEN: IARKAZ; ISSN: 0367-6846
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB cf. CA 58, 437g. A mixture of 0.5 mole acetylenic alc., 50 g. 32-35% H2CO in H2O, and 50 g. freshly prepared Cu2O catalyst was refluxed with stirring 10-15 hrs., the reaction product filtered, and, after removing H2O, the residue distilled in vacuo under N to give glycols with slight yellow color. In another procedure, the mixture of 0.4 mole paraformaldehyde, 0.4 mole acetylenic alc. or acetate, corresponding amount of catalyst, and 40-50 g. solvent was refluxed at 70-110° with stirring for 6-13 hrs., cooled, filtered, the solvent removed, and the residue distilled in vacuo. Thus were obtained RR'C(OH)C.tplbond.CCH2OH (R, R', % yield in cyclohexane, HCONMe2, xylene, and butanol, b.p./mm., n20D and d20 given): Me, Me, 75 (55 from aqueous CH2O), 72, 60, 67.1, 132°/15, 1.4755, 1.040; Me, Et, 70.4 (52 from aqueous CH2O), 67.3, 63.5, --, 135°/15, 1.4790, 1.012; (RR' =) (CH2)4, 68.6 (60 from aqueous CH2O), 70.2, 64, 65, 156-8°/15, 1.5050, 1.1039; (RR' =) (CH2)5, 86 (68, aqueous CH2O), 80, 73, 72.7, --, --, --; (RR' =) CH2CH2OCMe2CH2, 58 (45, aqueous CH2O), 49, --, --, 175-7°/15, 1.4925, 1.1038; MeCH2CH2, H, 35, 25, --, --, 142°/15, 1.4730, 1.032. Also obtained were RR'C(OAc)C.tplbond.CCH2OH (R, R', % yield in cyclohexanone, n20D and d20 given): Me, Me, 30, 140-7°/7, 1.471, 1.0709; (RR' =) (CH2)4, 47, 150-1°/5, 1.501, 1.1163; (RR' =) (CH2)5, 30, 155-7°/5, 1.503, 1.110. The acetylenic glycols and their acetates were hydrated by the method of Kucherov: glycol or its monoacetate (10 g.), 40 ml. H2O, and 2 g. HgSO4 were mixed at room temperature 1 hr., the temperature increased to 60° over 2 hrs. with stirring and the mixture stirred 1 hr. at 80° gave I (R, R', % yield, b.p./mm., n20D, and d20 given): Me, Me, 52, 138°/680, 1.4310, 0.990 (semicarbazone m. 180°); Me, Et, 55, 74-5°/25, 1.4370, 0.981 (semicarbazone m. 154-5°); (RR' =) (CH2)4, 38, 64°/3, 1.4710, 1.063 (dinitrophenylhydrazone m. 132-3°); (RR' =) (CH2)5, 60, 113-14°/25, 1.4768, 1.068 (semicarbazone m. 172-3°); (RR' =) CH2CH2OCMe2CH2, 30, 66°/1, 1.440, 0.996 (dinitrophenylhydrazone m. 107-8°). Catalyst can be used for several expts.

L17 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1960:110441 CAPLUS
DN 54:110441

OREF 54:21032h-i,21033a-c
TI Oxidation of unsymmetric tetra-and trisubstituted 3-furanidones with selenium dioxide
AU Korobitsyna, I. K.; Pivnitskii, K. K.; Yur'ev, Yu. K.
CS State Univ. Moscow
SO Zhurnal Obshchei Khimii (1959), 29, 3880-4
CODEN: ZOKHA4; ISSN: 0044-460X
DT Journal
LA Unavailable
AB cf. CA 52 4659i. Refluxing 30 g. 3-methyl-1-(1-hydroxycyclopentyl)-1-butyn-3-ol in 200 ml. H2O with 15 g. HgSO4 suspended in 30 ml. H2O 4.5 hrs. gave 65.5% 2,2-dimethyl-5,5-tetramethylene-3-furanidone (I) mixed with the 4-isomer, b3 64.8-5.8° n20D 1.4583 d20 0.9708 which gave a mixture of 2,4-dinitrophenylhydrazones, separated by crystallization from MeOH-petr.
ether to yield a 10:1 ratio of the more soluble isomer, m. 136-7°, and the less soluble isomer, m. 158.5-9.5°. Similarly 3-methyl-1-(1-hydroxycyclohexyl)-1-butyn-3-ol in 8 hrs. gave 80.5% 2,2-dimethyl-5,5-pentamethylene-3-furanidone (II), mixed with the 4-isomer, b3 71.5-2.2°, 1.4632, 0.9940, which gave the 2,2,4-dinitrophenylhydrazones, m. 159.2-9.3°, and m. 228.5-9.5°, in 4:1 ratio. 2-Methyl-5-phenyl-3-hexyne-2,5-diol in 15 hrs. gave 55.5% pure 2,2,5-trimethyl-5-phenyl-3-furanidone (III), b7 119.5-20°, 1.5083, 1.0406; 2,4-dinitrophenylhydrazone, m. 160-60.5°. The mixed I (16.8 g.) added over 0.5 hr. to a refluxing mixture of 14 g. SeO2 in 10 ml. H2O and 200 ml. dioxane and the mixture refluxed 12 hrs. gave 82.5% 2,2-dimethyl-5,5-tetramethylenefuranidine-3,4-dione, b3 86-7°, m. 29.5-30°. In air this formed a colorless hydrate; dioxime decomposed 206-6.5°; quinoxaline derivative m. 106°. Mixed isomers of II gave 87.5% hygroscopic 2,2-dimethyl-5,5-pentamethylenefuranidine-3,4-dione, b4 98-100°, m. 68.5-70°; dioxime decomposed 187-8°, quinoxaline derivative m. 127°. III gave 84.5% 2,2,5-trimethyl-5-phenylfuranidine-3,4-dione, b2 110°, 1.5140, 1.1066, which could not be obtained in a completely pure state; heating with o-phenylenediamine gave the quinoxaline derivative, m. 73.1-4.6°.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	204.39	672.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-38.81	-38.81

STN INTERNATIONAL LOGOFF AT 09:24:41 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:34:57 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:35:06 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.6

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:35:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5031 TO ITERATE

100.0% PROCESSED 5031 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 09:35:46 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
STRUCTURE TOO LARGE - SEARCH ENDED
A structure in your query is too large. You may delete attributes or atoms to reduce the size of the structure and try again.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	156.05

STN INTERNATIONAL LOGOFF AT 09:36:08 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:37:10 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:37:19 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.7

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:37:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1433 TO ITERATE

100.0% PROCESSED 1433 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 09:37:48 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:37:57 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 272 TO ITERATE

100.0% PROCESSED 272 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.05

L3 0 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 109.42 265.05

FILE 'CAOLD' ENTERED AT 09:38:09 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGistRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:38:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1433 TO ITERATE

100.0% PROCESSED 1433 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

L5 0 L4

=> log y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.42 421.31

STN INTERNATIONAL LOGOFF AT 09:38:21 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:39:38 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:39:48 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.8

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:40:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 45 TO ITERATE

100.0% PROCESSED 45 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 09:40:19 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:40:25 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 107 TO ITERATE

100.0% PROCESSED 107 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.42	265.05

STN INTERNATIONAL LOGOFF AT 09:40:51 ON 13 MAR 2004

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09  CA/CAplus records now contain indexing from 1907 to the
                  present
 NEWS  4  DEC 08  INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29  DISSABS now available on STN
 NEWS  6  OCT 10  PCTFULL: Two new display fields added
 NEWS  7  OCT 21  BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28  BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24  MSDS-CCOHS file reloaded
 NEWS 10  DEC 08  CABA reloaded with left truncation
 NEWS 11  DEC 08  IMS file names changed
 NEWS 12  DEC 09  Experimental property data collected by CAS now available
                  in REGISTRY
 NEWS 13  DEC 09  STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17  DGENE: Two new display fields added
 NEWS 15  DEC 18  BIOTECHNO no longer updated
 NEWS 16  DEC 19  CROPU no longer updated; subscriber discount no longer
                  available
 NEWS 17  DEC 22  Additional INPI reactions and pre-1907 documents added to CAS
                  databases
 NEWS 18  DEC 22  IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22  ABI-INFORM now available on STN
 NEWS 20  JAN 27  Source of Registration (SR) information in REGISTRY updated
                  and searchable
 NEWS 21  JAN 27  A new search aid, the Company Name Thesaurus, available in
                  CA/CAplus
 NEWS 22  FEB 05  German (DE) application and patent publication number format
                  changes
 NEWS 23  MAR 03  MEDLINE and LMEDLINE reloaded
 NEWS 24  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS 25  MAR 03  FRANCEPAT now available on STN

 NEWS EXPRESS  MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:42:40 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:42:49 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.9

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 09:43:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1433 TO ITERATE

100.0% PROCESSED 1433 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 09:43:29 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:43:36 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 272 TO ITERATE

100.0% PROCESSED 272 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.05

L3 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.42	265.05

STN INTERNATIONAL LOGOFF AT 09:43:45 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:45:16 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:45:28 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.10

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 H,O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ss full
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s l1 sss full
FULL SEARCH INITIATED 09:46:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.84	156.05

FILE 'MARPAT' ENTERED AT 09:46:26 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 09:46:35 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 188321 TO ITERATE

2.4% PROCESSED	4472 ITERATIONS	0 ANSWERS
4.8% PROCESSED	9058 ITERATIONS	0 ANSWERS
6.9% PROCESSED	13000 ITERATIONS	0 ANSWERS
10.6% PROCESSED	20049 ITERATIONS	0 ANSWERS
13.3% PROCESSED	24999 ITERATIONS	0 ANSWERS
15.4% PROCESSED	29076 ITERATIONS	0 ANSWERS
19.0% PROCESSED	35835 ITERATIONS	0 ANSWERS
21.9% PROCESSED	41149 ITERATIONS	0 ANSWERS
24.1% PROCESSED	45471 ITERATIONS	0 ANSWERS
27.5% PROCESSED	51865 ITERATIONS	0 ANSWERS
29.0% PROCESSED	54704 ITERATIONS	0 ANSWERS
29.9% PROCESSED	56340 ITERATIONS	0 ANSWERS
30.9% PROCESSED	58253 ITERATIONS	0 ANSWERS
31.5% PROCESSED	59363 ITERATIONS	0 ANSWERS
31.8% PROCESSED	59831 ITERATIONS	0 ANSWERS
31.9% PROCESSED	60000 ITERATIONS	0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.04.20

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 188321 TO 188321
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS FUL L1

=> log y
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.62	269.67

STN INTERNATIONAL LOGOFF AT 09:52:57 ON 13 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:32:28 ON 13 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:32:40 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5
DICTIONARY FILE UPDATES: 12 MAR 2004 HIGHEST RN 662722-88-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10026606.14

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2,NH

G2 SO2,Ak

G3 Cb,Cy,Hy

G4 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 10:33:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1760 TO ITERATE

100.0% PROCESSED 1760 ITERATIONS 489 ANSWERS
SEARCH TIME: 00.00.01

L2 489 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 10:33:18 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full

STRUCTURE TOO LARGE - SEARCH ENDED
A structure in your query is too large. You may delete attributes or atoms to reduce the size of the structure and try again.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	156.05

FILE 'CAPLUS' ENTERED AT 10:33:32 ON 13 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 12 Mar 2004 (20040312/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d his

(FILE 'HOME' ENTERED AT 10:32:28 ON 13 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:32:40 ON 13 MAR 2004
L1 STRUCTURE UPLOADED
L2 489 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:33:18 ON 13 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:33:32 ON 13 MAR 2004
L3 2 S L2

=> d l4 fbib hitstr abs total
L4 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:521746 CAPLUS
DN 137:93770
TI Preparation of tricyclic spiro compounds and cholesterol biosynthesis inhibitors containing them as the active ingredient
IN Nishida, Hidemitsu; Mukaihira, Takafumi
PA Mochida Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053568	A1	20020711	WO 2001-JP11656	20011228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-399998 A	20001228
	EP 1346994	A1	20030924	EP 2001-272922	20011228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-399998 A	20001228
				WO 2001-JP11656W	20011228

PATENT FAMILY INFORMATION:
FAN 2001:31501

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-222883 A	19990630
	EP 1191028	A1	20020327	EP 2000-940912	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	BR 2000012093	A	20020716	BR 2000-12093	20000630
				JP 1999-222883 A	19990630
				WO 2000-JP4374 W	20000630
	ZA 2001010558	A	20020912	ZA 2001-10558	20011221
				JP 1999-222883 A	19990630
	US 2003045520	A1	20030306	US 2001-26606	20011227
				JP 1999-222883 A	19990630
				WO 2000-JP4374 A2	20000630
				JP 2000-399998 A	20001228

NO 2001006402 A 20020227 NO 2001-6402 20011228
JP 1999-222883 A 19990630
WO 2000-JP4374 W 20000630

OS MARPAT 137:93770

IT **441790-74-5P 441790-75-6P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 441790-74-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-75-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **318988-32-8P 441789-02-2P 441789-65-7P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 318988-32-8 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-02-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-65-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(3-furanylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **441790-18-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic

agents)

RN 441790-18-7 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(phenylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 318986-22-0P 441788-65-4P 441788-66-5P
441788-67-6P 441788-68-7P 441788-69-8P
441788-70-1P 441788-71-2P 441788-72-3P
441788-73-4P 441788-74-5P 441788-75-6P
441788-76-7P 441788-78-9P 441788-79-0P
441788-80-3P 441788-81-4P 441788-82-5P
441788-83-6P 441788-85-8P 441788-86-9P
441788-87-0P 441788-88-1P 441788-89-2P
441788-90-5P 441788-91-6P 441788-92-7P
441788-93-8P 441788-94-9P 441788-97-2P
441788-98-3P 441789-00-0P 441789-01-1P
441789-03-3P 441789-05-5P 441789-06-6P
441789-07-7P 441789-08-8P 441789-10-2P
441789-11-3P 441789-12-4P 441789-13-5P
441789-14-6P 441789-16-8P 441789-17-9P
441789-22-6P 441789-24-8P 441789-28-2P
441789-29-3P 441789-30-6P 441789-31-7P
441789-32-8P 441789-33-9P 441789-35-1P
441789-36-2P 441789-37-3P 441789-38-4P
441789-39-5P 441789-40-8P 441789-41-9P
441789-42-0P 441789-43-1P 441789-44-2P
441789-46-4P 441789-47-5P 441789-49-7P
441789-50-0P 441789-51-1P 441789-52-2P
441789-53-3P 441789-54-4P 441789-56-6P
441789-57-7P 441789-58-8P 441789-59-9P
441789-60-2P 441789-61-3P 441789-62-4P
441789-63-5P 441789-64-6P 441789-66-8P
441789-67-9P 441789-68-0P 441789-69-1P
441789-70-4P 441789-71-5P 441789-72-6P
441789-73-7P 441789-74-8P 441789-75-9P
441789-78-2P 441789-79-3P 441789-80-6P
441789-81-7P 441789-82-8P 441789-83-9P
441789-84-0P 441789-85-1P 441789-86-2P
441789-87-3P 441789-88-4P 441789-89-5P
441789-90-8P 441789-91-9P 441789-92-0P
441789-93-1P 441789-94-2P 441789-95-3P
441789-96-4P 441789-97-5P 441789-98-6P
441789-99-7P 441790-00-7P 441790-01-8P
441790-02-9P 441790-03-0P 441790-04-1P
441790-05-2P 441790-06-3P 441790-07-4P

441790-08-5P 441790-09-6P 441790-10-9P
441790-11-0P 441790-12-1P 441790-13-2P
441790-14-3P 441790-15-4P 441790-16-5P
441790-17-6P 441790-19-8P 441790-20-1P
441790-21-2P 441790-86-9P 441790-87-0P
441790-90-5P 441790-91-6P 441790-92-7P
441790-93-8P 441790-94-9P 441790-95-0P
441790-96-1P 441790-97-2P 441790-98-3P
441790-99-4P 441791-00-0P 441791-01-1P
441791-02-2P 441791-03-3P 441791-04-4P
441791-05-5P 441791-06-6P 441791-07-7P
441791-08-8P 441791-09-9P 441791-10-2P
441791-11-3P 441791-12-4P 441791-13-5P
441791-14-6P 441791-15-7P 441791-16-8P
441791-19-1P 441791-20-4P 441791-21-5P
441791-22-6P 441791-23-7P 441791-24-8P
441791-25-9P 441791-26-0P 441791-27-1P
441791-28-2P 441791-46-4P 441791-49-7P
441791-52-2P 441791-53-3P 441791-60-2P
441791-61-3P 441791-62-4P 441791-63-5P
441791-64-6P 441791-65-7P 441791-68-0P
441791-69-1P 441791-70-4P 441791-71-5P
441791-72-6P 441791-73-7P 441791-74-8P
441791-75-9P 441791-76-0P 441791-77-1P
441791-78-2P 441791-79-3P 441791-80-6P
441791-81-7P 441791-82-8P 441791-83-9P
441791-84-0P 441791-85-1P 441791-86-2P
441791-87-3P 441791-88-4P 441791-89-5P
441791-90-8P 441791-91-9P 441791-92-0P
441791-93-1P 441791-95-3P 441791-97-5P
441791-98-6P 441791-99-7P 441792-00-3P
441792-01-4P 441792-02-5P 441792-03-6P
441792-04-7P 441792-05-8P 441792-06-9P
441792-07-0P 441792-08-1P 441792-09-2P
441792-10-5P 441792-11-6P 441792-12-7P
441792-13-8P 441792-14-9P 441792-15-0P
441792-16-1P 441792-17-2P 441792-18-3P
441792-19-4P 441792-20-7P 441792-21-8P
441792-22-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 318986-22-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-65-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-66-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-65-4
CMF C23 H27 Br N4 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441788-67-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-8a-(ethoxymethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-68-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-69-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-70-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(3-chloro-4-pyridinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441788-71-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 441788-72-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441788-73-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 441788-74-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 441788-75-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 441788-76-7 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-78-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-79-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-80-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-81-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(4-bromobenzoyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-82-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-83-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-85-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-86-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(benzo[b]thien-2-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-87-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-88-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-89-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-5-fluorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-90-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-91-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-bromo-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-92-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-fluoro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-93-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-94-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylsulfonyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-97-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441788-98-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-[(4-bromophenyl)sulfonyl]tetrahydro-7-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-00-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(1H-indol-2-ylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-01-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-ethynyl-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-03-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 441789-05-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(phenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-06-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-07-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-08-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-10-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-11-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-12-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-13-5 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-14-6 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-16-8 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-17-9 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-22-6 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-24-8 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-28-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-69-8
CMF C21 H23 Br N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-29-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-8a-(methoxymethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-71-2
CMF C22 H25 Br Cl N5 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-30-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-72-3
CMF C20 H21 Br Cl N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-31-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-73-4
CMF C20 H22 Br N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-32-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinylmethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-75-6
CMF C22 H25 Br N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-33-9 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-76-7
CMF C21 H24 Br N5 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-35-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-78-9
CMF C21 H23 Cl N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-36-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-79-0

CMF C21 H24 N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-37-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-94-9
CMF C21 H30 N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-38-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-80-3
CMF C25 H26 N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-39-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(4-bromobenzoyl)tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-81-4
CMF C22 H23 Br N4 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-40-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-82-5
CMF C21 H23 F N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-41-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-97-2
CMF C22 H25 Br N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-42-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-[(4-bromophenyl)sulfonyl]tetrahydro-7-(4-pyridinylmethyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441788-98-3
CMF C22 H25 Br N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-43-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyridinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-02-2
CMF C22 H26 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-44-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-03-3
CMF C21 H23 Cl N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-46-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-05-5
CMF C23 H28 N4 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-47-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-08-8
CMF C25 H27 Cl N4 O5 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-49-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-10-2
CMF C25 H27 Cl N4 O6 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-50-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-12-4
CMF C26 H29 Cl N4 O6 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-51-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 441789-17-9
CMF C21 H25 N5 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 441789-52-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-53-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-54-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-56-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2,3-dihydro-1H-inden-2-yl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-57-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclohexyltetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-58-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(1-cyclohexen-1-ylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-59-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-phenylethenyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-60-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-61-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-62-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(3-phenylpropyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-63-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-phenylethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-64-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-66-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2-furanylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-67-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(4-phenylbutyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-68-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(3-phenyl-2-propenyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-69-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-70-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-methoxyphenyl)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-71-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-methylphenyl)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-72-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-73-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-74-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-hydroxyphenyl)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-75-9 CAPLUS
CN Benzonitrile, 4-[[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 441789-78-2 CAPLUS
CN Benzonitrile, 4-[2-[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 441789-79-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-80-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-81-7 CAPLUS
CN Benzonitrile, 2-[2-[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 441789-82-8 CAPLUS
CN Benzonitrile, 3-[2-[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 441789-83-9 CAPLUS
CN Benzoic acid, 4-[[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441789-84-0 CAPLUS
CN Benzoic acid, 4-[[tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 441789-85-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 441789-86-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-hydroxy-2-phenylethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-87-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-oxo-2-phenylethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-88-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3,4-dimethoxyphenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-89-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[2-(4-nitrophenyl)ethyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-90-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclopentyltetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-91-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclopropylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-92-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclobutyltetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-93-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-94-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methoxymethyl)phenyl]methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-95-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-oxazolylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-96-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(5-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 441789-97-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[2-(3-furanyl)ethyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-98-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-nitrophenyl)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441789-99-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-acetylphenyl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-00-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-[2-(3-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 441790-01-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(2-nitrophenyl)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-02-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methylsulfonyl)phenyl]methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-03-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2-benzofuranylmethyl)tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-04-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-05-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 441790-06-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-benzoyl-1'-(3-fluoro-4-pyridinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-07-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)-7-(3-furanylmethyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-08-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 441790-09-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)-1'-(3-fluoro-4-pyridinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-10-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-11-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-12-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 441790-13-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(2-chloro-4-pyrimidinyl)tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-14-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4,5-dihydro-2-oxazolyl)tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-15-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4,5-dihydro-2-thiazolyl)tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-16-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-nitrophenyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-17-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(2-nitrophenyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-19-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(2-phenylethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-20-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-21-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-hydroxy-1-phenylethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-86-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-87-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-90-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-91-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-92-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-(benzo[b]thien-2-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 441790-93-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-(benzo[b]thien-2-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 441790-94-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-95-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-96-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(5-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-97-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-5-fluorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-98-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-5-fluorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441790-99-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-00-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-01-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(5-bromo-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-02-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-[(5-bromo-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-03-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-[(5-fluoro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-04-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-fluoro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-05-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-06-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-07-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-7-(1H-indol-2-ylsulfonyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 441791-08-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-7-(1H-indol-2-ylsulfonyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 441791-09-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-ethynyl-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-10-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-ethynyl-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-11-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-12-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-13-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-14-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 441791-15-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-
(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-16-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-19-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-20-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry..



RN 441791-21-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-22-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chloro-6-quinolinyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-23-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-24-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-25-9 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-26-0 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-27-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-28-2 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,

7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-46-4 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,
7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-
(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-49-7 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,
7-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-
(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-52-2 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-53-3 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(5-chloro-2-benzofuranyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-60-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-1'-(4-pyridinyl)-7-(4-pyridinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-61-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(4-pyridinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-62-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-phenylethenyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 441791-63-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-phenylethenyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 441791-64-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-hydroxyphenyl)methyl]-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-65-7 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-hydroxyphenyl)methyl]-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-68-0 CAPLUS
CN Benzonitrile, 4-[2-[(8aR)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-69-1 CAPLUS
CN Benzonitrile, 4-[2-[(8aS)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-70-4 CAPLUS
CN Benzoic acid, 4-[[(8aR)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-71-5 CAPLUS
CN Benzoic acid, 4-[[(8aS)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-72-6 CAPLUS
CN Benzoic acid, 4-[[(8aR)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-

oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 441791-73-7 CAPLUS
CN Benzoic acid, 4-[[(8aS)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 441791-74-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3,4-dimethoxyphenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-75-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3,4-dimethoxyphenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-76-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclobutyltetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-77-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclobutyltetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-78-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methoxymethyl)phenyl]methyl]-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-79-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methoxymethyl)phenyl]methyl]-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-80-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(5-pyrimidinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-81-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(5-pyrimidinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-82-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-acetylphenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-83-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-acetylphenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-84-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(2-nitrophenyl)methyl]-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-85-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-[(2-nitrophenyl)methyl]-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-86-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methylsulfonyl)phenyl]methyl]-1'-(4-pyridinyl)-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-87-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[4-(methylsulfonyl)phenyl]methyl]-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-88-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2-benzofuranylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-89-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)-7-(3-furanylmethyl)tetrahydro-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-90-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

1'-(3-fluoro-4-pyridinyl)-7-(3-furanylmethyl)tetrahydro-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-91-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-phenylethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-92-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-phenylethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-93-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)-1'-(3-fluoro-4-pyridinyl)tetrahydro-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-95-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)-1'-(3-fluoro-4-pyridinyl)tetrahydro-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-97-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-naphthalenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-98-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(2-naphthalenylmethyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441791-99-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-00-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-01-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-nitrophenyl)-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-02-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-nitrophenyl)-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-03-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(2-nitrophenyl)-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-04-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(2-nitrophenyl)-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-05-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-8a-(methoxymethyl)-7-(phenylmethyl)-1'-(4-pyridinyl)-, (8aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-06-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-8a-(methoxymethyl)-7-(phenylmethyl)-1'-(4-pyridinyl)-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-07-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-8a-(methoxymethyl)-7-(2-phenylethyl)-1'-(4-pyridinyl)-, (8aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-08-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(2-phenylethyl)-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-09-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-10-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-(cyclohexylmethyl)tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-11-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-12-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-13-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-[(4-bromophenyl)sulfonyl]-8a-(ethoxymethyl)tetrahydro-1'-(4-pyridinyl)-,
(8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-14-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
7-[(4-bromophenyl)sulfonyl]-8a-(ethoxymethyl)tetrahydro-1'-(4-pyridinyl)-,
(8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-15-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-16-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-17-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(3-chloro-4-pyridinyl)tetrahydro-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-18-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(3-chloro-4-pyridinyl)tetrahydro-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-19-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-8a- (methoxymethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-20-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-8a-(methoxymethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-21-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-, (8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-22-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **441792-23-0P 441792-24-1P 441792-25-2P**
441792-26-3P 441792-27-4P 441792-28-5P
441792-29-6P 441792-30-9P 441792-33-2P
441792-34-3P 441792-35-4P 441792-36-5P
441792-37-6P 441792-38-7P 441792-39-8P
441792-40-1P 441792-41-2P 441792-42-3P
441792-43-4P 441792-44-5P 441792-49-0P
441792-50-3P 441792-51-4P 441792-52-5P
441792-55-8P 441792-56-9P 441792-59-2P
441792-60-5P 441792-61-6P 441792-62-7P
441792-63-8P 441792-64-9P 441792-67-2P
441792-68-3P 441792-69-4P 441792-70-7P
441792-71-8P 441792-72-9P 441792-73-0P
441792-74-1P 441792-75-2P 441792-76-3P
441792-77-4P 441792-78-5P 441792-79-6P
441792-80-9P 441792-81-0P 441792-82-1P
441792-83-2P 441792-84-3P 441792-85-4P
441792-86-5P 441792-87-6P 441792-88-7P
441792-89-8P 441792-90-1P 441792-91-2P
441792-92-3P 441792-93-4P 441792-94-5P
441792-95-6P 441792-96-7P 441792-97-8P
441792-98-9P 441792-99-0P 441793-00-6P
441793-03-9P 441793-04-0P 441793-05-1P
441793-06-2P 441793-07-3P 441793-08-4P
441793-09-5P 441793-10-8P 441793-11-9P
441793-12-0P 441793-13-1P 441793-14-2P
441793-15-3P 441793-16-4P 441793-17-5P
441793-18-6P 441793-19-7P 441793-20-0P
441793-21-1P 441793-22-2P 441793-23-3P
441793-24-4P 441793-25-5P 441793-26-6P
441793-27-7P 441793-28-8P 441793-29-9P
441793-30-2P 441793-31-3P 441793-32-4P
441793-33-5P 441793-34-6P 441793-35-7P
441793-36-8P 441793-37-9P 441793-38-0P
441793-39-1P 441793-40-4P 441793-41-5P
441793-42-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 441792-23-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-24-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-25-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-nitrophenyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-26-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-nitrophenyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-27-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-28-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-29-6 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-30-9 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-33-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 441792-34-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-35-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-36-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-37-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-38-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-39-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(4-bromobenzoyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-40-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(4-bromobenzoyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-41-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(4-fluorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-42-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-43-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-44-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylsulfonyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-49-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-50-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(4-bromophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-51-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-[(4-bromophenyl)sulfonyl]tetrahydro-7-(4-pyridinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-52-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-[(4-bromophenyl)sulfonyl]tetrahydro-7-(4-pyridinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-55-8 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-56-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-chloro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-59-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-60-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-61-6 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-62-7 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one,

tetrahydro-7-(phenylsulfonyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-63-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-pyridinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-64-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-pyridinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-67-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2,3-dihydro-1H-inden-2-yl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-68-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2,3-dihydro-1H-inden-2-yl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-69-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-cyclohexyltetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-70-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclohexyltetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-71-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(1-cyclohexen-1-ylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-72-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(1-cyclohexen-1-ylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-73-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-thienylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-74-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-thienylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-75-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(3-phenylpropyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-76-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(3-phenylpropyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-77-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-(2-phenylethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-78-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-phenylethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-79-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-80-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclohexylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-81-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(3-furanylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-82-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-(3-furanylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-83-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2-furanylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-84-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2-furanylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-85-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(4-phenylbutyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-86-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(4-phenylbutyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-87-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-(3-phenyl-2-propenyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 441792-88-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(3-phenyl-2-propenyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 441792-89-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-90-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-91-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-methoxyphenyl)methyl]-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-92-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-[(4-methoxyphenyl)methyl]-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-93-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-methylphenyl)methyl]-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-94-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-methylphenyl)methyl]-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-95-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-96-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-fluorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-97-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-(2-naphthalenylmethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-98-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-naphthalenylmethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441792-99-0 CAPLUS
CN Benzonitrile, 4-[[(8aR)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-00-6 CAPLUS
CN Benzonitrile, 4-[[(8aS)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-03-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(2-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-04-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(2-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-05-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-06-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(3-chlorophenyl)methyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-07-3 CAPLUS
CN Benzonitrile, 2-[2-[(8aR)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-08-4 CAPLUS
CN Benzonitrile, 2-[2-[(8aS)-tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[7H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-7-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-09-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-1'-(4-pyridinyl)-7-[(tetrahydro-2H-pyran-4-yl)methyl]-, (8aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-10-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-1'-(4-pyridinyl)-7-[(tetrahydro-2H-pyran-4-yl)methyl]-, (8aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-11-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,
tetrahydro-7-(2-hydroxy-2-phenylethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 441793-12-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-hydroxy-2-phenylethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-13-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-hydroxy-1-phenylethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-14-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-7-(2-hydroxy-1-phenylethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-15-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-oxo-2-phenylethyl)-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-16-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(2-oxo-2-phenylethyl)-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-17-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclopentyltetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-18-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-cyclopentyltetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-19-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclopropylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-20-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(cyclopropylmethyl)tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-21-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-thiazolylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-22-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(2-thiazolylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-23-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[2-(3-furanyl)ethyl]tetrahydro-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-24-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[2-(3-furanyl)ethyl]tetrahydro-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-25-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-nitrophenyl)methyl]-1'-(4-pyridinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-26-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[(4-nitrophenyl)methyl]-1'-(4-pyridinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-27-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

tetrahydro-1'-(4-pyridinyl)-7-[2-(3-thienyl)ethyl]-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-28-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-[2-(3-thienyl)ethyl]-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-29-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-30-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-31-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-32-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

1'-(3-fluoro-4-pyridinyl)tetrahydro-7-(phenylsulfonyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-33-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-benzoyl-1'-(3-fluoro-4-pyridinyl)tetrahydro-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-34-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-benzoyl-1'-(3-fluoro-4-pyridinyl)tetrahydro-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-35-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyrimidinyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-36-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)-1'-(4-pyrimidinyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-37-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

1'-(4,5-dihydro-2-oxazolyl)tetrahydro-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-38-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4,5-dihydro-2-oxazolyl)tetrahydro-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-39-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4,5-dihydro-2-thiazolyl)tetrahydro-7-(phenylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-40-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4,5-dihydro-2-thiazolyl)tetrahydro-7-(phenylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-41-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-pyridinylmethyl)-, (8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441793-42-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-(3-pyridinylmethyl)-, (8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **318988-26-0P 318988-27-1P 318988-28-2P**
441790-23-4P 441790-24-5P 441790-25-6P
441790-26-7P 441790-27-8P 441790-28-9P
441790-29-0P 441790-30-3P 441790-31-4P
441790-35-8P 441790-36-9P 441790-37-0P
441790-38-1P 441790-40-5P 441790-41-6P
441790-42-7P 441790-43-8P 441790-44-9P
441790-46-1P 441790-47-2P 441790-55-2P
441790-56-3P 441790-57-4P 441790-80-3P
441790-81-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic spiro compds. as oxidosqualene cyclase inhibitors and cholesterol biosynthesis inhibitors for preventives and therapeutic agents)

RN 318988-26-0 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-27-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-28-2 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-23-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-24-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-25-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-26-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-27-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 441790-28-9 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(4-bromophenyl)sulfonyl]tetrahydro-5-oxo-, 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 441790-29-0 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(4-bromophenyl)sulfonyl]tetrahydro-5-oxo-, 8a-ethyl 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 441790-30-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(4-bromophenyl)sulfonyl]tetrahydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 441790-31-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 441790-35-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-36-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-37-0 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-38-1 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(4-bromophenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-40-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-[[1-(phenylsulfonyl)-1H-indol-2-yl]sulfonyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 441790-41-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-1'-(4-pyridinyl)-7-[[5-[(trimethylsilyl)ethynyl]-2-benzofuranyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 441790-42-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-43-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-44-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-46-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-47-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-(2H-1-benzopyran-3-ylsulfonyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 441790-55-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-56-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 441790-57-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]tetrahydro-8a-(methoxymethyl)-(9CI) (CA INDEX NAME)



RN 441790-80-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, tetrahydro-5-oxo-7-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 441790-81-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



GI



I

AB Disclosed are orally administrable cholesterol biosynthesis inhibitors and oxidosqualene cyclase inhibitors which contain as the active ingredients tricyclic spiro compds., i.e. 1,4-diaza-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one and 1,4,7-triazaspiro[bicyclo[4.3.0]nonane-8,4'-

piperidine]-2-one derivs. represented by the general formula (I) or salts thereof: [wherein A = H, (un)substituted 5- or 6-membered (un)saturated heterocyclic or carbocyclic group, (un)substituted NH2 or imidoyl; B = a single bond, carbonyl, S(O)x (x = 0,1,2), C1-2 alkylene; D = H, COR5 (R5 = H, substituent), (un)substituted C1-6 alkyl; X = N, CH optionally substituted by A'-B' group (A' and B' are selected from groups defined in A and B, resp.); Y = O, S(O)y (y = 0,1,2), NH; Z = CH2, CO, C(:S); T = SO2, CO, S(O)z (z = 0,1,2), a single bond, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbon or heterocyclic group; m, n, p = 0,1, or 2, provided that m and p are not simultaneously 0; q = 0,1; each of 3 rings cong. X, Y, and Z is optionally substituted; the solid line accompanied by a dotted line represents a single bond or a double bond when q is 0]. These compds. inhibit oxidosqualene cyclase and in turn the conversion of 2,3-oxidosqualene into cholesterol and thereby exhibit potent serum cholesterol lowering effect and are useful for the prevention and/or treatment of cholesterol biosynthesis and oxidosqualene cyclase-related diseases such as hypercholesteremia, hyperlipidemia, arteriosclerotic disease, myocardial infarction, angina pectoris, cerebral infarction, cerebral hemorrhage, aortic aneurysm, peripheral artery obstruction, nephrosclerosis, optic nerve atrophy, hydrocephalus, and fungal infection. Thus, Et3N and 4-bromobenzenesulfonyl chloride were added to a son. of 1,4-diaza-4-(benzyloxycarbonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one in CH2Cl2 and stirred at room temperature for 10 min to give 1,4-diaza-4-(benzyloxycarbonyl)-1'-(4-bromobenzenesulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one which was dissolved in MeCN, treated with trimethylsilyl iodide under ice-cooling, and stirred for 30 min under ice-cooling to give 1,4-diaza-1'-(4-bromobenzenesulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonane-8,4'-piperidine]-2-one (II). II at 0.3 μg/mL in vitro inhibited the biosynthesis of cholesterol in mouse fibroblast L929 cells by 66%.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31501 CAPLUS
DN 134:100887
TI Preparation of tricyclic compounds having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants
IN Nishida, Hidemitsu; Saitoh, Fumihiko; Harada, Kousuke; Shiromizu, Ikuya
PA Mochida Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002397	A1	20010111	WO 2000-JP4374	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-222883 A	19990630

EP 1191028	A1	20020327	EP 2000-940912	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			JP 1999-222883 A	19990630
			WO 2000-JP4374 W	20000630
BR 2000012093	A	20020716	BR 2000-12093	20000630
			JP 1999-222883 A	19990630
			WO 2000-JP4374 W	20000630
ZA 2001010558	A	20020912	ZA 2001-10558	20011221
			JP 1999-222883 A	19990630
US 2003045520	A1	20030306	US 2001-26606	20011227
			JP 1999-222883 A	19990630
			WO 2000-JP4374 A2	20000630
			JP 2000-399998 A	20001228
NO 2001006402	A	20020227	NO 2001-6402	20011228
			JP 1999-222883 A	19990630
			WO 2000-JP4374 W	20000630

PATENT FAMILY INFORMATION:

FAN 2002:521746

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002053568	A1	20020711	WO 2001-JP11656	20011228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-399998 A	20001228
EP 1346994	A1	20030924	EP 2001-272922	20011228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			JP 2000-399998 A	20001228
			WO 2001-JP11656W	20011228

OS MARPAT 134:100887

IT **318986-36-6P 318986-38-8P 318987-69-8P 318987-70-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318986-36-6 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 318986-38-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-69-8 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 318987-70-1 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,

7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **318986-22-0P 318986-60-6P 318986-68-4P**
318986-74-2P 318986-78-6P 318986-80-0P
318987-02-9P 318987-14-3P 318987-29-0P
318987-31-4P 318987-33-6P 318987-35-8P
318987-37-0P 318987-39-2P 318987-41-6P
318987-46-1P 318987-51-8P 318987-52-9P
318987-54-1P 318987-56-3P 318987-60-9P
318987-61-0P 318987-62-1P 318987-63-2P
318987-64-3P 318987-65-4P 318987-66-5P
318987-67-6P 318987-72-3P 318987-73-4P
318987-74-5P 318987-75-6P 318987-76-7P
318987-77-8P 318987-78-9P 318987-79-0P
318987-80-3P 318987-81-4P 318987-82-5P
318987-83-6P 318987-84-7P 318987-85-8P
318987-86-9P 318987-87-0P 318987-88-1P
318987-90-5P 318987-91-6P 318987-95-0P
318987-96-1P 318987-97-2P 318987-98-3P
318987-99-4P 318988-01-1P 318988-02-2P
318988-04-4P 318988-06-6P 318988-07-7P
318988-08-8P 318988-09-9P 318988-10-2P
318988-13-5P 318988-15-7P 318988-16-8P
318988-20-4P 318988-21-5P 318988-25-9P
318988-26-0P 318988-32-8P 318988-38-4P
318988-40-8P 318988-41-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318986-22-0 CAPLUS

CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318986-60-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318986-68-4 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318986-74-2 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 318986-78-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318986-80-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-02-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-14-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318987-29-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-22-0
CMF C27 H29 Cl N4 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-31-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)-, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-38-8
CMF C27 H29 Cl N4 O5 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-33-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 318986-64-0
CMF C26 H27 Cl N4 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-35-8 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-68-4
CMF C30 H33 Cl N4 O7 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-37-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318986-80-0
CMF C28 H29 Cl N4 O6 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-39-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-02-9
CMF C25 H25 Cl N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-41-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-14-3
CMF C24 H24 Cl N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-46-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-51-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-46-1
CMF C29 H33 Cl N4 O6 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-52-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-hydroxyethoxy)methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-54-1 CAPLUS
CN Pyridinium, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]-1-methyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 318987-53-0
CMF C28 H32 Cl N4 O5 S



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



RN 318987-56-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 318987-60-9 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-56-3
CMF C28 H29 Cl N4 O6 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-61-0 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-62-1 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 318987-63-2 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 318987-64-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, propyl ester (9CI) (CA INDEX NAME)



RN 318987-65-4 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 318987-66-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 318987-67-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 318987-72-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-70-1
CMF C28 H29 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-73-4 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-74-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-75-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1-methylethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-76-7 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid,

7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, propyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-77-8 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-propenyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-78-9 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-methoxyethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-79-0 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1,1-dimethylethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 318987-80-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, methyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-74-5
CMF C27 H27 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-81-4 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1-methylethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-75-6
CMF C29 H31 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 318987-82-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, propyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-76-7
CMF C29 H31 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-83-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-propenyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-77-8

CMF C29 H29 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-84-7 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 2-methoxyethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-78-9
CMF C29 H31 Cl N4 O7 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-85-8 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, 1,1-dimethylethyl ester, (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-79-0
CMF C30 H33 Cl N4 O6 S

Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-86-9 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ammonium salt (9CI) (CA INDEX NAME)



● NH_3

RN 318987-87-0 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ammonium salt, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● NH_3

RN 318987-88-1 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ammonium salt, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● NH_3

RN 318987-90-5 CAPLUS
CN Pyridinium, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-(ethoxycarbonyl)tetrahydro-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]-1-ethyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 318987-89-2
CMF C30 H34 Cl N4 O6 S



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



RN 318987-91-6 CAPLUS
CN Benzenecarboximidamide, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-

piperidin]-1'-yl]- (9CI) (CA INDEX NAME)



RN 318987-95-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 318987-96-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(1-oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318987-97-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(1-iminoethyl)- (9CI) (CA INDEX NAME)



RN 318987-98-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(1-iminoethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318987-97-2
CMF C22 H25 Cl N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318987-99-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-(aminomethyl)-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-01-1 CAPLUS
CN Carbamic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-02-2 CAPLUS
CN Glycine, N-[[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-04-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(4-morpholinylmethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-06-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(4-morpholinylmethyl)-1'-(4-pyridinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318988-04-4
CMF C30 H34 Cl N5 O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318988-07-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]-1'-(2-chloro-4-pyrimidinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 318988-08-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]tetrahydro-7-(2-naphthalenylsulfonyl)-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318988-09-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318988-10-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318988-13-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-15-7 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 318988-16-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-20-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-(4-pyridinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 318988-16-8
CMF C26 H27 Cl N4 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 318988-21-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 318988-25-9 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)-, ammonium salt (9CI) (CA INDEX NAME)



RN 318988-26-0 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-32-8 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-38-4 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-40-8 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- , (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 318988-41-9 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, tetrahydro-8a-(methoxymethyl)-7-(2-naphthalenylsulfonyl)-1'-(4-pyridinyl)- , (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **318986-28-6P 318986-30-0P 318986-32-2P**
318986-34-4P 318986-40-2P 318986-42-4P
318986-44-6P 318986-57-1P 318986-62-8P
318986-64-0P 318986-66-2P 318986-70-8P
318986-72-0P 318986-76-4P 318986-89-9P
318987-09-6P 318987-11-0P 318987-16-5P
318987-47-2P 318987-48-3P 318987-49-4P
318987-50-7P 318987-57-4P 318987-58-5P
318987-59-6P 318987-71-2P 318987-93-8P
318987-94-9P 318988-00-0P 318988-03-3P
318988-05-5P 318988-11-3P 318988-12-4P
318988-14-6P 318988-18-0P 318988-19-1P
318988-23-7P 318988-24-8P 318988-27-1P
318988-28-2P 318988-34-0P 318988-35-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. having spiro-piperidine as inhibitors of blood coagulation factor X (FXa) and anticoagulants or as pharmacophores in mol. designing Fxa inhibitors)

RN 318986-28-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318986-30-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318986-32-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318986-34-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-40-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 318986-42-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 318986-44-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 318986-57-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 318986-62-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 318986-64-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318986-66-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-70-8 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(phenylmethyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318986-72-0 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxospiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318986-76-4 CAPLUS
CN Acetic acid, [[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-8a-yl]methoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 318986-89-9 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 318987-09-6 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318987-11-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318987-16-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 318987-47-2 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-[(2-ethoxy-2-oxoethoxy)methyl]tetrahydro-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 318987-48-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-hydroxyethoxy)methyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 318987-49-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1'-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 318987-50-7 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[(2-methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 318987-57-4 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 318987-58-5 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-1',8a-dicarboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, 8a-ethyl 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 318987-59-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 318987-71-2 CAPLUS
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (-)-ethyl 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 318987-70-1
CMF C28 H29 Cl N4 O6 S

Rotation (-).



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry.



RN 318987-93-8 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 1'-(4-aminophenyl)-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 318987-94-9 CAPLUS
CN Benzenecarboximidic acid, 4-[7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-5-oxospiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-1'-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-00-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one,

7-[(6-chloro-2-naphthalenyl)sulfonyl]-8a-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]tetrahydro-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-03-3 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxaldehyde, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-05-5 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1'-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 318988-11-3 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 318988-12-4 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 318988-14-6 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-carboxylic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-[2-(methylthio)-4-pyrimidinyl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 318988-18-0 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-19-1 CAPLUS
CN Spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-methyl- (9CI) (CA INDEX NAME)



RN 318988-23-7 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-1'-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 318988-24-8 CAPLUS
CN Spiro[8aH-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-8a-butanoic acid, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 318988-27-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-28-2 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 318988-34-0 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(hydroxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318988-35-1 CAPLUS
CN Spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one, 7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-8a-(methoxymethyl)-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



GI



I



II

AB Aromatic compds. having cyclic amino which are represented by general formula (I) or salts thereof [wherein A = H, (un)substituted (un)saturated 5- to 6-membered cyclic hydrocarbyl or heterocyclyl, (un)substituted NH2, (un)substituted imidoyl; B = single bond, CO, SO, (un)substituted C1-2 alkylene; D = H, (un)substituted CHO, (un)substituted C1-6 alkyl; X = N, (un)substituted methine; Y = O, S(O)y (wherein y = 0,1,2), (un)substituted NH; Z = CH2, CO, C(S); T = S(O)z (wherein z = 0,1,2), CO, (un)substituted C1-2 alkylene; Q = (un)substituted hydrocarbyl or heterocyclyl; m, n, q = 0, 1,2; p = 0,1; the three rings containing X, Y, or Z is optionally substituted; the bond represented by a dotted and solid line in the ring containing Z is a single bond or a double bond when p = 0] are prepared These compds. are useful as drugs, in particular, activated blood coagulation factor X inhibitors for the prevention and treatment of diseases caused by thrombus or embolism, influenza virus infection, or periodontosis, exert a potent anticoagulation effect, and can be orally administered. A pharmacophore derived from the above compds. is also useful in mol. designing Fxa inhibitors. Thus, 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine was cyclocondensed with Et 2-[N-(3-acetoxy-2-oxopropan-1-yl)-N-(6-chloronaphthalene-2-ylsulfonyl)amino]acetate under reflux in the presence of p-MeC6H4SO3H.H2O using a Dean-Stark trap to give 6-acetoxy-1,4-diaza-1'-benzyl-4-(6-chloronaphthalene-2-ylsulfonyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one which underwent saponification with a mixture of aqueous NaOH and MeOH, methylation by di-Me sulfate, and debenzylation with 1-chloroethyl chloroformate to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxaspiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one hydrochloride. The latter compound was condensed with 4-chloropyridine hydrochloride in the presence of diisopropylethylamine in 2-ethoxyethanol under reflux for 2 h to give 1,4-diaza-4-(6-chloronaphthalene-2-ylsulfonyl)-6-(methoxymethyl)-7-oxo-1'-(4-pyridyl)-spiro[bicyclo[4.3.0]nonan-8,4'-piperidine]-2-one (II; R = CH2OMe). II (R = CH2OMe) and II (R = CO2Et) showed IC50 of 0.0032 and 0.0015 μM, resp., against Fxa.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	22.99	179.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.39	-1.39

STN INTERNATIONAL LOGOFF AT 10:34:52 ON 13 MAR 2004

L Number	Hits	Search Text	DB	Time stamp
1	536	("544/358").CCLS	USPAT	2004/03/13 11:23
2	361	("544/380").CCLS	USPAT	2004/03/13 11:23
3	227	("544/384").CCLS	USPAT	2004/03/13 11:24
4	978	("514/248").CCLS	USPAT	2004/03/13 11:24
5	441	("514/245").CCLS	USPAT	2004/03/13 11:24
6	765	("514/250").CCLs	USPAT	2004/03/13 11:25
7	2731	("514/252").CCLS	USPAT	2004/03/13 11:25
8	424	("514/252.13").CCLS	USPAT	2004/03/13 11:26
9	0	(("544/358").CCLS) and (("544/380").CCLS) and (("544/384").CCLS)	USPAT	2004/03/13 11:26
10	114	(("514/248").CCLS) and (("514/245").CCLS) and (("514/250").CCLs) (("514/252").CCLS) and (("514/252.13").CCLS)	USPAT	2004/03/13 11:26

L Number	Hits	Search Text	DB	Time stamp
1	536	("544/358").CCLS	USPAT	2004/03/13 11:23
2	361	("544/380").CCLS	USPAT	2004/03/13 11:23
3	227	("544/384").CCLS	USPAT	2004/03/13 11:24
4	978	("514/248").CCLS	USPAT	2004/03/13 11:24
5	441	("514/245").CCLS	USPAT	2004/03/13 11:24
6	765	("514/250").CCLs	USPAT	2004/03/13 11:25
7	2731	("514/252").CCLS	USPAT	2004/03/13 11:25
8	424	("514/252.13").CCLS	USPAT	2004/03/13 11:26
9	0	(("544/358").CCLS) and (("544/380").CCLS) and (("544/384").CCLS)	USPAT	2004/03/13 11:26
10	114	(("514/248").CCLS) and (("514/245").CCLS) and (("514/250").CCLs) (("514/252").CCLS) and (("514/252.13").CCLS)	USPAT	2004/03/13 11:26
11	235	("540/543").CCLS	USPAT	2004/03/13 11:27
12	504	("540/553").CCLS	USPAT	2004/03/13 11:28
13	149	("540/557").CCLS	USPAT	2004/03/13 11:28
14	97	("540/569").CCLS	USPAT	2004/03/13 11:28
15	65	("540/570").CCLS	USPAT	2004/03/13 11:28
16	156	("540/547").CCLS	USPAT	2004/03/13 11:29
17	2002	("514/183").CCLS	USPAT	2004/03/13 11:29
18	161	("514/211.01").CCLS	USPAT	2004/03/13 11:29
19	55	("514/211.03").CCLS	USPAT	2004/03/13 11:30
20	41	("514/211.04").CCLS	USPAT	2004/03/13 11:30
21	141	("514/211.08").CCLS	USPAT	2004/03/13 11:30
22	0	(("540/543").CCLS) and (("540/553").CCLS) and (("540/557").CCLS) and (("540/569").CCLS) and (("540/569").CCLS) and (("540/570").CCLS) and (("540/547").CCLS)	USPAT	2004/03/13 11:31
23	0	(("514/183").CCLS) and (("514/211.01").CCLS) and (("514/211.03").CCLS) and (("514/211.04").CCLS) and (("514/211.08").CCLS)	USPAT	2004/03/13 11:33
24	398734	factor Xa and spiro	USPAT	2004/03/13 11:34
25	2094	(factor Xa and spiro) and tricyclic	USPAT	2004/03/13 11:34
26	17	((factor Xa and spiro) and tricyclic) and nonan	USPAT	2004/03/13 11:34
27	17	(((factor Xa and spiro) and tricyclic) and nonan) and one	USPAT	2004/03/13 11:39
28	98	spiro and decan	USPAT	2004/03/13 11:40
29	97	(spiro and decan) and one	USPAT	2004/03/13 11:40
30	11330	((spiro and decan) and one) and factor XA	USPAT	2004/03/13 11:40
32	3308	(((spiro and decan) and one) and factor XA) and thrombin	USPAT	2004/03/13 11:40
31	1	((spiro and decan) and one) and thrombin	USPAT	2004/03/13 11:41